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Bcl-2 protein family regulates the commitment of cells to apoptosis, an 
ancient cell suicide programme that is vital for development, immunity and 
tissue homeostasis. While excessive apoptosis augments ischemic conditions 
and promotes neuro-degeneration, shortage of apoptosis drives cancer and 
auto-immune diseases. By regulating the activation and oligomerization of 
Bax and Bak in the outer mitochondria membrane (OMM), the Bcl-2 protein 
family control the release of apoptogenic factors from mitochondria. MOAP-1, 
initially named MAP-1 (modulator of apoptosis-1) has previously been cloned 
as a Bax-associating protein from a yeast-two hybrid screen using Bax as bait. 
Similar to other Bcl-2 family proteins, MOAP-1 is enriched in the OMM. In 
healthy cells, MOAP-1 is a short-lived protein (t
1/2
~25mins) which is 
constitutively degraded by the ubiquitin proteasome system (UPS). Apoptotic 
stimuli stabilize MOAP-1 and induce its association with Bax in mitochondria. 
Notably, loss of function analysis suggests MOAP-1 is a critical effector for 
Bax-mediated apoptosis in mitochondria. Correspondingly, higher levels of 
MOAP-1 sensitize cancer cells to chemotherapeutic drugs, suggesting 
mechanisms that are directly involved in regulating its protein stability can 
potentially be valuable targets for cancer treatment. However, the molecular 
mechanism of how MOAP-1 sensitizes cancer cells to chemotherapeutic drugs 
remains unknown. 
Post-translational modifications (PTMs) modulate protein function in 
eukaryotes and have a ubiquitous role in diverse range of cellular functions. 
An in-depth understanding of the roles of PTMs in modulating protein 
stability of MOAP-1 is vital not only for gaining perception of a wide array of 
ix 
 
potential cellular functions of MOAP-1 but may also be crucial for 
conceptualizing therapeutic strategies aimed at modulating the protein 
abundance of MOAP-1. In this study, we examined ubiquitination, 
phosphorylation and acetylation as prospective PTM regulatory mechanisms 
of MOAP-1. For the investigation on the ubiquitination of MOAP-1, we show 
that tripartite motif protein 11 (TRIM11) associates with and degrades MOAP-
1 via the UPS-mediated mechanisms. Targeted inactivation of putative 
TRIM11 E3 activity by alanine substitution on conserved cysteine or histidine 
residues in the RING domain abolished its ability to poly-ubiquitinate and 
degrade MOAP-1. Collectively, our data support a role for TRIM11 as a 
putative E3 ubiquitin ligase of MOAP-1. As for the examination on 
phosphorylation of MOAP-1, we revealed that protein stability of MOAP-1 is 
regulated by phosphorylation at serine-27 (Ser-27), Ser-29 and Ser-31 and that 
over-expression of constitutive active MAPK kinase (MEK1Δ) can up-
regulate and stabilize MOAP-1. Constitutive phosphorylation at these three 
serine residues by aspartate substitution prolongs the half-life of MOAP-1 and 
is required for MEK1Δ-mediated stabilization of MOAP-1. In agreement with 
its effect on enhancing MOAP-1 stability, MEK1Δ sensitizes cancer cells to 
TRAIL-induced Bax-activation and apoptosis. Together, our data support a 
role for MEK1Δ in modulating the stability of MOAP-1 through 
phosphorylation at Ser27, Ser-29 and Ser-31. Lastly, we identified SIRT2 and 
SIRT5, which are members of the sirtuin family of deacetylases, as novel 
interactors of MOAP-1. Our data support a role for SIRT5 in mediating the 
regulation of MOAP-1 under DNA-damaging agent, ETOP.  
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In conclusion, this study explored ubiquitination, phosphorylation and 
acetylation as prospective PTM regulatory mechanisms for regulating the 
protein stability of MOAP-1, providing further insight to enhance our 
understanding of the mechanisms that serve to regulate MOAP-1 stability. 
Hence, TRIM11, MEK1Δ and SIRT5 may be explored as potential targets to 
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Apoptosis or programmed cell death, is an essential aspect of life for 
multi-cellular organisms (1). The term originates from a Greek word 
“απόπτωσις” which signifies the shedding of leaves from trees in autumn. 
While the observation was first described by Carl Vogt, a German scientist in 
1842, the word “apoptosis” was primarily proposed and coined only in 1972 
by three British scientists Kerr J.F., Wyllie A.H. and Currie A.R. to describe a 
morphologically distinct form of cell death (2). Apoptosis is acknowledged as 
a critical and distinctive mode of programmed cell death. It plays an essential 
role in the development of the embryo and the elimination of superfluous, 
ectopic, damaged or mutated cells in multi-cellular organisms (3). The 
importance of apoptosis is evidenced with it being a highly conserved process 
that has evolved across species to maintain cell numbers and cellular 
positioning within tissues (4-6).  
Through the decades, many forms of programmed cell death have been 
described such as necrosis, necroptosis (programmed necrosis) as well as other 
forms of programmed cell death yet to be discovered. However, apoptosis is 
distinctive as it is orderly and does not cause inflammation to neighbouring 
healthy cells. Typically, cells undergoing apoptosis are characterized by 
several distinctive morphological and molecular changes (6). Cell shrinkage, 
membrane surface blebbing, chromatin condensation, DNA fragmentation, 
externalization of phosphatidylserine and ultimately the breakdown of the cell 
into membrane-enclosed vesicles known as ‘apoptotic bodies’ are examples of 
 Chapter 1 
3 
 
characteristic morphological and biochemical features associated with 
apoptosis (Fig 1.1) (7-11). In addition, a key feature of activated apoptosis is 
the cleavage of cytoskeletal proteins by cysteine-dependent aspartate-directed 
proteases (caspases) which thereby results in the collapse of sub-cellular 
components (12). In most cases, apoptotic bodies are eliminated by 
neighbouring phagocytic cells. The externalization of phosphatidylserine 
results in the recruitment of macrophages to engulf these apoptotic bodies. In 
doing so, inflammatory response and damage to neighbouring healthy cells are 




Figure 1.1 Morphology of apoptotic cells. A. The left panel shows healthy HeLa 
cells while the right panel shows cells displaying characteristic apoptotic morphology 
including cell shrinkage and plasma membrane blebbbing. B. Features of apoptotic 
nuclear condensation and fragmentation. HeLa cells were induced to undergo 
apoptosis followed by staining of the nuclei (blue) with Hoechst dye. For comparison, 
a mixture of healthy and apoptotic cells is shown. Apoptotic cells (indicated with 
white arrows) exhibit extensive plasma membrane blebbing and contain nuclei that 
are condensed and/or fragmented into several pieces. Figure is reproduced and 
adapted from  (14).  
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Greater understanding of apoptosis was achieved from the analysis of 
programmed cell death during the development of the nematode 
Caenorhabditis elegans (15). In this organism, 1090 somatic cells are created 
in the development of the adult worm, of which 131 of these cells will 
undergo apoptosis. The precise death of these 131 cells demonstrates the 
extraordinary accuracy and precise control in this process. It is not surprising 
then that improper functioning of apoptosis signaling has been linked to a 
plethora of human ailments, ranging from neuro-degenerative disease to 
cancer (16).  
1.1.2 Apoptotic cell death and diseases 
Increased apoptosis has been associated with and contributed to acute 
ischemic diseases associated with reperfusion injury, such as myocardial 
infarction, stroke and renal hypoxia (17,18). In neurological disorders 
including, but not limited to, Alzheimer’s, Parkinson’s and Huntington’s 
diseases, specific neurons prematurely commit suicide which can result in 
irreversible memory loss, uncontrolled muscular movements and depression 
(19,20). Involvement of increased apoptosis in arteriosclerosis, infertility, 
AIDS, diabetes and hepatitis have also been reported (18,21). Decreased 
apoptosis is known to be involved in cancer and auto-immune disorders. In 
many forms of cancers, key pro-apoptotic proteins are mutated and/or anti-
apoptotic proteins are frequently up-regulated leading to the accumulation of 
cells and the inability of these cancer cells to response well to chemo-
therapeutic agents (22). Since effective chemotherapy depends on the proper 
induction of apoptosis, cancers with defects in the apoptosis signaling 
pathways are particularly difficult to treat. Over the years, research into 
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apoptosis has generated much enthusiasm that key proteins in the apoptosis 
signaling pathway that are targetable by small molecular weight compounds 
could be promising drug targets to selectively induce apoptosis in cancer cells 
(12).  
1.1.3 Extrinsic and intrinsic pathways of apoptosis 
Higher eukaryotes possess two major pathways for initiating apoptosis: 
the cell-extrinsic death pathway involving death receptors and the cell-
intrinsic pathway that is regulated by Bcl-2 family of proteins (Fig 1.2). The 
former is activated by death-inducing ligands binding to cell surface receptor 
while the latter is activated by diverse intrinsic signals converging at the 
mitochondria. Both pathways involve the initiation and amplification of 
caspase cascades (23). Caspases are the key effectors of apoptosis. They are 
normally present in healthy cells as zymogens or pro-enzymes with low or no 
enzymatic activity and require proteolytic activation at aspartate sites to 
produce the mature, catalytically active forms (24). As illustrated in Fig 1.2, 
the initiation of early caspase activation is different between the extrinsic 
death-receptor-mediated and intrinsic mitochondrial-mediated pathways. 
Although in certain cell types, the extrinsic cell death-receptor-mediated 
pathway does not require mitochondria involvement to activate caspases, the 
extrinsic and intrinsic pathways do converge at the mitochondria in most cell 
types, underscoring the broad and central role serves by the mitochondria in 
apoptosis execution in mammals (25). For that reason, the mitochondria play a 
central role in controlling apoptosis events by integrating up-stream apoptosis-
inducing signals and regulating the release of apoptogenic factors such as 
cytochrome c and diablo homologue (SMAC/DIABLO). 




Figure 1.2 Extrinsic and intrinsic pathways of cellular apoptosis. There are two 
major pathways of apoptosis: the death-receptor pathway, which is mediated by the 
activation of death receptors, and the Bcl2-regulated mitochondrial pathway, which is 
mediated by noxious stimuli that ultimately lead to mitochondrial injury. Ligation of 
death receptors recruits the adaptor protein FAS-associated death domain (FADD). 
FADD in turn recruits caspase 8, which ultimately activates caspase 3, the key 
effector caspase. In contrast to the extrinsic death-receptor-mediated pathway utilized 
by a limited set of death stimuli, the intrinsic mitochondrial-mediated pathway 
integrates a broad range of extra-cellular and intra-cellular stresses such as DNA 
damage, unbalanced proliferative stimuli and nutrient or energy depletion (26). In the 
intrinsic mitochondrial-mediated pathway, pro-apoptotic BH3-only proteins are 
activated by noxious stimuli which interact with and inhibit anti-apoptotic Bcl-2 or 
Bcl-xL. Thus, Bax and Bak are free to induce mitochondrial permeabilization with 
the release of cytochrome c. Cytochrome c released from the mitochondria binds to 
the adaptor molecule apoptotic protease activating factor (APAF-1) in the presence of 
ATP to form a large complex term apoptosome which results in the activation of 
caspase 9. Caspase 9 then activates caspase 3. SMAC/DIABLO is also released after 
mitochondrial permeabilization and acts to block the action of inhibitors of apoptosis 
protein (IAPs such as XIAP) which inhibit caspase activation. In addition, the 
truncated form of Bid (tBid) which is generated by caspase 8-mediated proteolysis of 
BID in the extrinsic death receptor-mediated pathway, can engage the mitochondria 
pathway to amplify the apoptotic response. This amplification mechanism is required 
for effective apoptosis in certain cells (denoted ‘type 2’ cell) such as hepatocytes but 
not in ‘type 1’ cells such as thymocytes (27,28). The level of XIAP distinguishes the 
two cell types as it is typically higher in type 2 cells. The figure is reproduced and 
adapted from (12). 
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1.2 BCL-2 FAMILY PROTEINS: LIFE/DEATH SWITCH IN 
MITOCHONDRIA 
1.2.1 Mitochondria as the central organelle for apoptosis regulation 
Mitochondria are ubiquitous membrane-enclosed organelles that 
undertake multiple critical functions in a cell. They exert both vital and lethal 
functions in physiological and pathological scenarios (29). For instance, while 
mitochondria are indispensible for energy production and hence for the 
survival of eukaryotic cells; they are also the key regulators of the intrinsic 
pathway of apoptosis (30). Mitochondrial control the activation of apoptotic 
effect mechanisms by regulating the translocation of apoptogenic factors from 
the mitochondrial intermembrane space to the cytosol (Fig 1.3) (29).  
Besides their role in apoptosis and energy production, the mitochondria 
also regulate calcium homeostasis and host several other metabolic circuitries 
including, but not limited to, the Krebs cycle, the urea cycle, gluconeogenesis, 
ketogenesis, heme biosynthesis, fatty acid β-oxidation, steroidogenesis and 
amino acids metabolism. As the mitochondria play critical roles in numerous 
bio-energetic, anabolic and cell-death-inducing biochemical pathways, it is not 
surprising that the mitochondrial dysfunction have been contributed to the 
development of a plethora of human diseases which range from highly tissue-
specific conditions to generalized whole-body disorders including cancer 
(31,32). In the same context, multiple hallmarks of cancer cells including, but 
not limited to, proliferative potential, resistance to anti-growth signals, 
impaired apoptosis and decreased autophagy have been correlated with 
mitochondrial dysfunction (33).  





Figure 1.3 Schematic illustration of the mitochondrion and its role in regulating 
apoptosis. Mitochondria contain inner and outer membranes composed of 
phospholipid bilayers and proteins. The outer mitochondrial membrane encloses the 
entire organelle and contains porins that are involved in the transport of molecules ≤ 
5kDa. Larger molecules require active transport by mitochondrial membrane 
transport proteins. The inner mitochondrial membrane is compartmentalized into 
numerous cristae which increase the surface area of the inner mitochondrial 
membrane and hence maximize its ATP generation capacity (34). Under 
physiological conditions, the mitochondria exhibit a high mitochondrial 
transmembrane potential (ΔΨm) which is generated by the respiratory chain and 
exploited for ATP production via oxidative phosphorylation. However, in the 
presence of apoptotic signals, pro-apoptotic BAX and BAK oligomerization results in 
the dissipation of the ΔΨm and in the osmotic swelling of the mitochondrial matrix 
which eventually leads to mitochondrial outer membrane permeabilization (MOMP) 
and the release of apoptogenic factors normally confined within the mitochondrial 
intermembrane space (IMS) into the cytosol. Once in the cytosol, these factors 
activate caspase-dependent and –independent mechanisms that altogether mediate the 
execution of cell death. The figure is reproduced and adapted from (29). 
 
In 1972, Kerr et al. proposed in their seminal paper that the 
mitochondria appeared normal during apoptosis and hence it was initially 
believed that apoptosis was controlled at the nuclear level (35). This belief 
was further supported by evidence showing that cells lacking mitochondrial 
DNA are still able to under apoptosis (36). However, indirect evidence seems 
to suggest a possible role of mitochondria in apoptosis. Early investigation on 
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the Bcl-2 protein demonstrated that Bcl-2 localized in the mitochondria and 
the lack of the C-terminal transmembrane domain was found to diminish its 
ability to inhibit apoptosis (37,38). However, the earliest direct evidence 
demonstrating the involvement of mitochondria in apoptosis was conducted in 
a cell-free model system by Reed and colleagues in 1994 (39). The authors 
discovered that a dense organelle fraction enriched in mitochondria from 
Xenopus egg extracts was able to induce chromatic condensation, shrinkage 
and fragmentation of the nuclei, all of which were characteristic hallmarks of 
apoptosis. Shortly, mitochondrial permeability transition was published as the 
point-of-no-return, a critical event leading to cell death via intrinsic apoptosis 
and subsequently, the involvement of mitochondria in apoptosis was proposed 
(40,41). A breakthrough in the understanding of the involvement of 
mitochondria in apoptosis was the discovery of the release of cytochrome c 
from the mitochondria resulting in the initiation of the caspase cascades 
(42,43).  This finding strongly established an active role of mitochondria in the 
regulation of apoptosis signaling pathway and the molecular mechanism of 
apoptotic cell death.    
1.2.2 Regulation of mitochondrial outer membrane permeabilization by 
Bcl-2 family of proteins 
While the molecular networks and mechanisms regulating apoptosis 
signaling in mitochondria are still being actively investigated, the B-cell 
lymphoma (Bcl-2) family of proteins is widely recognized as the key 
regulators in the intrinsic mitochondrial-mediated apoptosis pathway. The Bcl-
2 family which includes 17 or more members in mammalian cells (16) 
functions as ‘life/death switch’ that integrates diverse inter- and intra-cellular 
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signals to determine whether or not the stress apoptosis pathway should be 
activated (44). They are characterized by the presence of several conserved 
motifs known as the Bcl-2 homology (BH) domains (45). The Bcl-2 family 
comprises of three major subfamilies; the multi-domain anti-apoptotic, pro-
apoptotic and the BH3-only pro-apoptotic proteins (Fig 1.4) in which 
interactions between proteins within the three subfamilies will regulate the 
‘life/death switch’.  
In a healthy cell, the pro-apoptotic proteins such as Bax and Bak are 
kept in check by the pro-survival Bcl-2 proteins. Bcl-2, Bcl-xL and Mcl-1 are 
the major members of the anti-apoptotic Bcl-2 repertoire and they preserve the 
outer mitochondrial membrane integrity by direct sequestration to neutralize 
the pro-apoptotic Bcl-2 proteins (46,47). For instance, the BH1 to BH3 
domains of Bcl-xL are in close proximity and create a hydrophobic pocket that 
can accommodate a BH3 domain of the pro-apoptotic proteins, thereby 
preventing them from perturbing the integrity of the outer mitochondrial 
membrane.  
However, when the cell is subjected to death-inducing stimuli such as 
DNA damage, growth factor deprivation or endoplasmic reticulum (ER) stress, 
the pro-apoptotic BH3-only proteins are activated. The BH3-only proteins 
function as damage sensors by acting as antagonists of Bcl-2 and other anti-
apoptotic proteins. Depending on the individual BH3-only protein, some such 
as Bad and Noxa bind to the anti-apoptotic Bcl-2 repertoire and thus inhibiting 
the anti-apoptotic function of these proteins (48-50) while others such as tBid, 
Puma and Bim are capable of directly inducing Bax and Bak activation (48-
54). Undeniably, triple genetic deletion of Bid, Bim and Puma abolished the 
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homo-oligomerization of Bax and Bak and thereby the cytochrome c-mediated 
activation of caspases in response to diverse death signals suggesting that the 
activation of Bax and Bak is fully dependent on Bid, Bim and Puma (54). An 
important biochemical difference between Bax and Bak is that in healthy cells, 
Bax is largely cytosolic or loosely associated with mitochondria while Bak is 
an integral membrane protein on the cytosolic face of the mitochondrion and 
ER. Hence, in response to cytotoxic signals, only Bax will translocate to the 
mitochondria whereby both Bax and Bak will undergo conformational 
changes to form membrane-associate homo-oligomers appearing as foci on the 
mitochondria (55,56). Remarkably, either action by the BH3-only proteins will 
facilitate homo-oligomerization of pro-apoptotic multi-domains Bax and Bak 
into the pore within the outer mitochondrial membrane, thereby promoting 
mitochondrial outer membrane permeabilization (MOMP) and ultimately 
apoptotic cell death (57,58). Thus the interplay among the Bcl-2 family 
proteins is crucial for Bax/Bak activation and the subsequent commitment of 
intrinsic mitochondria-mediated apoptosis (59-61).  
Murine embryonic fibroblasts (MEFs) with Bax or Bak deletion 
displayed no defect in apoptosis but MEFs with Bax and Bak double 
knockouts, surprisingly showed dramatic resistance to diverse apoptotic 
stimuli, suggesting Bax and Bak are central, but redundant effectors of 
mitochondrial-mediated apoptotic signaling (62). Analysis on apoptosis 
signaling events in human cell lines and tumor tissues, however, suggests that 
Bax may exert a dominant function over Bak in human context (63,64). 





Figure 1.4 Classification of the Bcl-2 family of proteins based on conservation of 
BH domains. The three main subfamilies are indicated as anti-apoptotic, pro-
apoptotic and BH3-only. BH1 to BH4 are the four conserved sequence motifs. Multi-
domain pro-apoptotic proteins and anti-apoptotic members share BH 1-3 domains 
while the BH3-only proteins contain only a single domain of homology. The figure is 
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1.2.3 Identification of MOAP-1 as a critical effector of Bax-mediated 
apoptosis 
MOAP-1, initially named as MAP-1 (modulator of apoptosis 1) was 
identified as a binding partner of Bax in a yeast two hybrid screen by our 
laboratory more than a decade ago (65). Notably, MOAP-1 is also found to 
belong to the Paraneoplastic Ma antigens (PNMA) family which comprises of 
six members, PNMA1-6 in human and is designated as PNMA4. MOAP-
1/PNMA4 was first studied independently from the PNMA family and it is the 
best characterized member up to date. Remarkably, similar to other members 
of the Bcl-2 family of proteins, endogenous MOAP-1 is found to be enriched 
at the outer membrane of mitochondria (66). While northern blot analysis 
showed that mRNA of MOAP-1 is ubiquitously expressed in most organs, the 
protein level of MOAP-1 is only readily detected in the mouse tissues of brain 
and testis. (65). Subsequent works revealed that MOAP-1 is a short-lived 
protein with a half-life of approximately 25 mins (Fig. 1.5A) and is 
constitutively degraded by the ubiquitin proteasome system (UPS) under non-
apoptotic condition (Fig. 1.5B) (67). On contrary, apoptotic stimuli induce the 
stabilization of MOAP-1 (Fig. 1.5C) and its integration and association with 
Bax in mitochondria (Fig. 1.5D) (66). Functional analysis showed that knock-
down of MOAP-1 by siRNA in tumour cell-lines conferred inhibition of 
apoptotic signaling triggered by multiple apoptotic stimuli and promoted their 
growth in anchorage-independent fashion (Fig. 1.5E) (66). Similarly, isolated 
mitochondria from the MOAP-1 knockdown cells were markedly resistant to 
Bax-induced cytochrome c release (Fig. 1.5F) (65). Taken together, these data 
support the notion that MOAP-1 is a critical facilitator of Bax-mediated 
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apoptosis signaling in mitochondria (66). Interestingly, MOAP-1 has also been 
shown to be a binding partner of tumor suppressor protein, Ras associating 
domain-containing protein 1 (RASSF1A) (68). RASSF1A specifically links 
cell death receptor and activated Ras-mediated signaling to Bax activation 
through MOAP-1. However the precise mechanism of how RASSF1A 
facilitate the interaction between MOAP-1 and Bax remains to be further 
investigated. Although MOAP-1 has been demonstrated to play a significant 
role in modulating Bax-mediated apoptosis, further exploratory investigation 
will be required to evaluate its role in other cellular aspects such as cell cycle, 
autophagy or inflammation. Likewise, cellular factors that regulate the protein 
stability of MOAP-1 are not yet fully elucidated.    
 
 Chapter 1 
15 
 
Figure 1.5 Known regulation and function of MOAP-1. A. Inhibition of de novo 
protein synthesis caused rapid elimination of endogenous MOAP-1. B. Proteasomal 
inhibition by MG132 resulted in the up-regulation of endogenous MOAP-1. C. 
Levels of endogenous MOAP-1 protein were rapid elevated by various apoptotic 
stimuli. D. Apoptotic stimuli promote endogenous MOAP-1-Bax association. E. 
MOAP-1 knockdown MCF-7 cells are resistance to apoptotic death triggered by UV. 
F. MOAP-1 is required to facilitate Bax-mediated release of cytochrome c from 
isolated mitochondria. The data were reproduced and adapted from (66,67).  
 
1.3 POST-TRANSLATIONAL MODIFICATIONS (PTMs) REGULATE 
PROTEIN ABUNDANCE AND FUNCTION 
Signaling pathways that regulate cell survival and cell death are 
complex. The cellular survival or apoptotic response is often determined by 
the expression levels, post-translational modifications (PTMs) and protein-
protein interaction profiles influencing the function of Bcl-2 protein family 
members (69). PTMs including, but not limited to, ubiquitination, 
phosphorylation and acetylation represent highly effective ways for reversible 
and rapid alteration of the cellular function of a protein (69,70). Multi-site 
PTMs of proteins modulate protein intrinsic functional activity, folding and 
conformation, oligomerization state, stability and half-life, turnover rate, sub-
cellular localization and protein-protein interactions (69,71). For instance, 
poly-ubiquitination may mark and target proteins for degradation through the 
ubiquitin proteasome system (UPS) while phosphorylation may determine 
whether a protein is recognized and targeted by its E3 ubiquitin ligase for 
degradation via the UPS. In general, majority of the PTMs target specific 
amino acids at specific recognition motifs and will often involve the covalent 
attachment of a specific chemical moiety to the respective amino acid residues 
on proteins. For instance, ubiquitination and acetylation target the lysine 
residues while phosphorylation results in the covalent attachment of a 
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phosphate group to the serine, threonine and/or tyrosine residues of a protein. 
Interestingly, cells of multi-cellular organisms have extensive networks of 
PTMs, whereby different modification pathways converge in signal 
integration. Moreover, the functional and inter-connected network of multiple 
PTMs between distinctive proteins orchestrates the overall cellular response 
by fine-tuning the functional activity of proteins (69).  Depending on the 
proteins involved and the cellular context, PTMs can result in either the 
promotion or inhibition of apoptosis (69). The dynamic interplay between the 
pro-apoptotic and anti-apoptotic family members is tightly controlled so as to 
ensure the survival or death of a cell within the appropriate cellular context.   
Like many proteins, the abundance and function of Bcl-2 family 
proteins are regulated by PTMs. It is generally accepted that the molecular 
regulation of a protein is linked to a highly orchestrated cascade of 
phosphorylation/dephosphorylation events that are intermingled with 
ubiquitination/de-ubiquitination, acetylation/deacetylation and other PTMs. 
One example is that of the molecular regulation of Mcl-1 (myeloid cell 
leukemia 1), an anti-apoptotic Bcl-2 family protein. Being anti-apoptotic, Mcl-
1 suppresses the progression of apoptosis by directly associating with and 
sequestering pro-apoptotic multi-domain proteins Bak and Bax, deterring the 
homo-oligomerization of Bax/Bak into the outer mitochondrial membrane 
thereby preventing MOMP and the release of apoptogenic factors such as 
cytochrome c into the cytosol. Mcl-1 also binds to and sequesters pro-
apoptotic BH3-only Bim which acts as an activator for Bax and Bak. Notably, 
Mcl-1 was reported to be rapidly regulated and degraded by the poly-
ubiquitination-mediated degradation pathway [also known as the ubiquitin 
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proteasome system, (UPS)] (72). Interestingly, phosphorylation of Mcl-1 by 
GSK-3 promotes its targeting and poly-ubiquitination by its E3 ubiquitin 
ligase, β-TrCP (73). Conversely, Mcl-1 has also been shown to be the target of 
a deubiquitinases, named USP9X, which results in the stabilization of Mcl-1 
by reversing its poly-ubiquitination thereby preventing its degradation through 
the UPS (74). These findings support the notion that PTMs work cooperatively 
on Bcl-2 family proteins such as Mcl-1 to regulate their function thereby 
promoting cell survival or apoptosis depending on the cellular context and the 
nature of the cell survival or cell death stimuli.  
1.3.1 Ubiquitination 
1.3.1.1 Poly-ubiquitination-mediated protein degradation 
Ubiquitin is a highly evolutionarily conserved 76 amino acid residue 
that is ubiquitously expressed in all eukaryotic tissues. Ubiquitination or the 
conjugation of ubiquitin to the protein substrate proceeds via a three-step 
cascade enzymatic mechanism involving E1 ubiquitin-activating enzyme, E2 
ubiquitin-conjugating enzyme and E3 ubiquitin ligases (Fig 1.6) (75). In a 
ubiquitin, there are seven lysine residues to which free ubiquitin can be 
conjugated, thus giving rise to seven different linkages (76). In addition, 
ubiquitin molecules may form a linear chain through their N-terminal 
methionine residue (Fig 1.6a). Mono-ubiquitination and multiple mono-
ubiquitination normally mediate membrane protein endocytosis and 
endosomal sorting (77,78). For poly-ubiquitination, poly-ubiquitination chains 
formed via the lysine 48 of the ubiquitin (K48-linked poly-ubiquitination, Fig 
1.6b) is the most commonly observed linkage which results in the degradation 
 Chapter 1 
18 
 
of proteins via the ubiquitin-proteasome system (UPS) (Fig 1.7) (79). 
Remarkably, it was estimated that about 80-90% of intracellular proteins are 
degraded by the UPS with the remaining 10-20% degraded by the lysosome 
(80,81).  
 
Figure 1.6 An overview of the multi-step enzymatic reaction of ubiquitination. In 
step (1), an ubiquitin molecule (Ub) is activated by an E1 ubiquitin-activating enzyme, 
resulting in the conjugation of the ubiquitin to a cysteine residue via a thioester bond 
in the active site of the E1 enzyme. This step requires the hydrolysis of an adenosine 
tri-phosphate (ATP), which is converted into an adenosine di-phosphate (ADP) and 
phosphate group, releasing energy to drive this E1-ubiquitin conjugation. In step (2), 
the E1 transfers the ubiquitin to a cysteine residue in the active site of the E2 enzyme. 
In step (3), the E2 ubiquitin conjugate then binds to an E3 ubiquitin ligase which 
recognizes its specific substrate protein and serves as a scaffold to allow the transfer 
of ubiquitin from the E2 to (usually) a lysine residue in the protein substrate (for 
RING-type E3s) or catalyzes the transfer via its ligase domain (for HECT-type E3s). 
The first three steps can be repeated to form a poly-ubiquitin chain on the substrate. 
The generation of poly-ubiquitin chains can occur at any one of the seven ubiquitin 
lysine residues and E2 conjugating enzymes may help to specific the linkage type in 
poly-ubiquitin chains. (a) Linear ubiquitination: Ubiquitin molecules may form a 
linear chain through their N-terminal methionine (Met1) (82). (b) K48-linked poly-
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ubiquitination: Poly-ubiquitination chains formed via the lysine (Lys) 48 of the 
ubiquitin usually target proteins for degradation via the ubiquitin proteasome system 
(83-85). (c) K63-linked poly-ubiquitination: Poly-ubiquitination chains formed via 
the lysine 63 of the ubiquitin target proteins for lysosomal degradation and other non-
proteolytic roles such as membrane protein endocytosis, DNA repair and activation of 
protein kinases (77,86-88). This type of modification does not appear to involve 
proteolysis of the target substrates but plays a role in the activation/inactivation of the 
target protein. Lastly in step (4), deubiquitinases (DUB) may disassemble the 
ubiquitin chains, removing the ubiquitin molecules from the protein substrates (75). 




Figure 1.7 Schematic representation of the ubiquitin-proteasome system (UPS). 
Degradation of poly-ubiquitinated substrates is carried out by a large multi-protein 
complex referred to as the 26S proteasome (80). It is composed of a 20S catalytic 
core (CP) formed by four rings containing two types of catalytic subunits (α and β) 
and two 19S regulatory subunits (RP) (80,90).  The regulatory subunit consists of 
multiple ubiquitin binding proteins (also known as ubiquitin receptors), ATPases, 
deubiquitinases and other adaptor proteins. Upon recognition by the ubiquitin 
receptors, ubiquitinated substrates are unfolded by ATPases and deubiquitinases 
reverse the covalent conjugation, resulting in the release of free ubiquitin (Ub) for 
recycling. The unfolded substrates are subsequently translocated into the 20S 
catalytic core of the proteasome through the opening of a narrow gated channel. The 
catalytic core contains a high number of proteolytic active sites that cleave the protein 
substrate into small peptides. The small peptides are then discharged from the base of 
the proteasome. Figure is reproduced and adapted from (91). 
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1.3.1.2 E3 ubiquitin ligases 
E3 ubiquitin ligases are key regulatory elements of the UPS as they 
confer substrate specificity and catalyze the last step in the conjugation of the 
ubiquitin to the substrate. Typically, the human ubiquitin system is believed to 
encode two E1s, approximately 50 E2s and over 500 E3s, forming an E1-E2-
E3 hierarchical pyramid (80,89). Based on the sequence homology of their E2-
binding domains, E3 ubiquitin ligases are mainly categorized into two main 
groups: HECT (homologous with E6-associated protein C-terminus)-type E3 
ubiquitin ligases and RING (Really Interesting New Gene)-type E3 ubiquitin 
ligases (Fig 1.8). The RING-type E3 ubiquitin ligases are the most abundant 
E3 ligases identified in eukaryotes to date (92,93) and they are known as 
RING-type E3 ubiquitin ligases due to the possession of a catalytic RING 
finger domain (94). Similarly, the HECT-type E3 ubiquitin ligases are 
characterized on the basis of their large C-terminal HECT domain which is a 
protein module of approximately 350 amino acids that was first identified in 
the E6-associated protein (E6-AP) (95). Possessing the HECT domain as the 
catalytic domain, HECT-type E3 ubiquitin ligases have intrinsic catalytic 
activity and can interact with E2 ubiquitin-conjugating enzymes and protein 
substrates directly without the need for adaptor or auxiliary proteins (95). The 
major difference between RING-type and HECT-type E3 ubiquitin ligases is 
that RING-type E3 ligases mediate the direct transfer of the ubiquitin straight 
from the E2 ubiquitin-conjugating enzymes to the protein substrates whereas 
the HECT-type E3 ubiquitin ligases first transfer the ubiquitin to themselves 
before conjugating it to the substrates (95,96).  
 





Figure 1.8 Two main types of E3 ubiquitin ligases. (A) HECT-type E3 ubiquitin 
ligase transfer ubiquitin from E2 ubiquitin-conjugate enzymes to a cysteine residue in 
their active sties before conjugating the ubiquitin onto the protein substrate. HECT-
type E3 ligases normally function on their own and they contain domains that allow 
interaction with E2 enzymes and substrate recognition domains that allow binding to 
their specific targeted protein substrates. (B) RING-type E3 ubiquitin ligases typically 
serve as a scaffold, bringing the substrate proteins in close proximity to the E2 
ubiquitin-conjugating enzymes, thereby mediating the direct transfer of ubiquitin 
from the active sites of E2 enzymes to the protein substrates. (C) RING-type E3 
ubiquitin ligases are characterized by a RING domain which produces a ‘cross-brace’ 
motif that is stabilized by the biding of two zinc atoms through cysteine and histidine 
residues. Figure is modified and adapted from (97). 
 
1.3.1.3 TRIM family of proteins as E3 ubiquitin ligases 
Notably, the RING finger motif is defined as a unique linear series of 
conserved cysteine and histidine residues. As illustrated in Fig 1.8c, the RING 
finger motif is composed of a unique “cross-brace” arrangement with two zinc 
ions and it folds into a compact domain comprising of a small central β sheet 
and an α helix (98,99). Frequently, the RING domain is associated with 
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cysteine-rich B-box domains followed by a predicted coiled-coil domain. This 
ensemble of a RING domain, one or two B-box domains and a coiled-coil 
domain are called RBCC or TRIM (100). Indeed, studies have reported 
RBCC/TRIM family of proteins functioning as E3 ubiquitin ligases with 
specific substrates identified. For instance, TRIM2 was identified as the E3 
ubiquitin ligase that ubiquitinates cell death-promoting protein Bcl-2-
interacting mediator of cell death (Bim) (101). It was previously reported that 
phosphorylation of the serine 65 residue by ERK1/2 is a critical event in the 
degradation of Bim (102). Notably, the ubiquitination and degradation of Bim 
by TRIM2 are blocked by inhibition of the MAPK cascade with MEK 
inhibitor, U0126 (refer to Section 1.3 for discussion on the MEK-ERK MAPK 
cascade). This example demonstrates the interplay between two PTMs in 
which phosphorylation of a protein permits the subsequent poly-ubiquitination, 
which is required for recognition and degradation by the UPS. In addition, 
TRIM proteins have also been reported to regulate the stability of other E3 
ubiquitin ligases, thereby modulating the protein abundance of substrates of 
the targeted E3s. For example, TRIM39 was previously demonstrated by our 
laboratory to be a binding partner of MOAP-1 that stabilizes MOAP-1 through 
inhibition of its poly-ubiquitination process (103). It was later revealed by 
another group that the influence of TRIM39 on MOAP-1 stems from the 
ability of TRIM39 to directly inhibit APC/C
Cdh1
-mediated MOAP-1 








1.3.2.1 Phosphorylation, a major protein regulatory mechanism 
Phosphorylation, a widely exploited PTM used in signal transduction 
to control cellular homeostasis (105), is thus far the most commonly reported 
protein modification that occurs in mammalian cells (106). Functioning as a 
form of spatial and temporal regulation on proteins, phosphorylation shares 
similarities with ubiquitin conjugation in regards to its reversibility. 
Remarkably, nearly 30% of all eukaryotic cellular proteins are phosphorylated 
and chromosomal mapping indicates that 244 of 518 kinase genes are disease- 
or cancer- related, demonstrating its ubiquity and importance in signal 
transduction (70,107). Phosphorylation involves the transfer of the terminal 
phosphate of adenosine tri-phosphate (ATP) to a hydroxyl group of an amino 
acid principally on serine (Ser), threonine (Thr) or tyrosine (Tyr) residues of 
most proteins (Fig 1.9). Because each phosphate group carries two negative 
charges, the addition of a phosphate group may change the protein 
conformation and consequently the functional activity of the protein. In this 
context, the ability of phosphorylation to alter the conformation of a protein 
allows for regulated control on the activity of the protein.  
Enzymes that phosphorylate proteins (protein kinases) and those that 
remove phosphates (protein phosphatases) usually activate or inactivate a 
particular protein. Protein kinases may be classified by their substrate 
specificity. Eukaryotes have different kinases that phosphorylate Ser/Thr or 
Tyr but all eukaryotic kinases typically will fold into a similar active site with 
an activation loop and catalytic loop between which substrates bind. 
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Phosphatases may be grouped into phospho-Tyr phosphatases, phospho-
Ser/Thr phosphatases and those that cleave both. Unlike kinases which differ 
in their structure of their catalytic domains, many phosphatases gain 
specificity by binding protein co-factors which facilitate the translocation and 
binding to specific phospho-proteins. The active phosphatase hence often 
consists of a complex of the catalytic subunit and a regulatory subunit. Some 
examples of important phosphatases include protein phosphatase 1 (PP-1), 
protein phosphatase 2A/B/C and protein Tyr-phosphatases 1B. Hence, the 
phosphorylation status of a protein is often determined by the delicate balance 
of kinases and phosphatases (108,109). The interplay between kinases and 
phosphatases turns ‘on’ or ‘off’ pathways within cells, thereby playing an 
important role in many intracellular signaling pathways (108).  
 
 
Figure 1.9 Schematic illustration of phosphorylation and dephosphorylation of a 
protein. Proteins are phosphorylated by kinases in an ATP-dependent manner while 
the removal of a phosphate group is catalyzed by protein phosphatases. Figure is 
modified and adapted from (110). 
 
1.3.2.2 MAPK and PI3K signaling cascades 
The activation of kinases by extracellular signals in signaling cascades 
such as the mitogen activated protein kinase (MAPK) and phosphatidylinositol 
3-kinase (PI3K) signaling cascades have been extensively studied. The MAPK 
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cascades are evolutionarily conserved, ubiquitous signaling modules that 
couple receptor-mediated events at the cell surface to cytosolic and nuclear 
effectors, regulating many basic cellular processes including, but not limited to, 
apoptosis, proliferation, differentiation and migration (111,112). All MAPK 
signaling cascades use a similar signal-relay mechanism that involves the 
sequential phosphorylation and activation of three kinases: MAPK kinase 
kinase (MAPKKK), MAPK kinase (MAPKK) and MAP kinase (MAPK) (Fig 
1.10). MAPKs are activated by dual phosphorylation on a conserved Thr-xxx-
Tyr motif in their activation loop by upstream MAPKKs which are activated 
by dual phosphorylation by MAPKKKs (113). There are three major families 
of MAPK: the extracellular signal regulated protein kinase (ERK1/2); the c-
Jun NH2 terminal kinase (JNK); and the p38 MAPKs, all of which respond to 
differing extracellular stimuli, resulting in a myriad of outcomes for cellular 
growth and proliferation. A handful of other MAPKs including ERK3 and 
ERK5 have been discovered but are less well understood (113). Due to the 
complex nature of these signaling pathways, only the activation of the Ras-




Figure 1.10 Schematic representation of signaling through classical MAPK 
cascades. Activation of the MAPKKK activates a MAPKK and the successive 
activation of the corresponding MAPK. Figure is modified and adapted from (113). 






Figure 1.11 Activation of the RAS-Raf-MEK-ERK MAPK signaling cascade. 
Activation of the pathway occurs when extracellular ligands such as chemokines, 
growth factors and hormones bind to the cytokine receptors, receptor tyrosine kinase 
(RTKs) and G-protein couple receptors (GPCRs) respectively (114-116). Ligand 
binding to the extracellular domain of the receptors triggers the activation of the 
kinase in the cytosolic domain. This activation results in the phosphorylation of the 
C-terminal tyrosine residues that allows docking of the Src homology 2 (SH2) 
domain in adaptor proteins such as the growth-factor-receptor bound protein-2 
(GRB2) (116). Adaptor protein GRB2 then recruits effector proteins such as guanine-
nucleotide exchange factor son-of-sevenless (SOS) to the plasma membrane 
promoting the exchange of GDP for GTP on GTPase RAS, thereby activating RAS 
which is anchored at the cytosolic side of the plasma membrane. Activated RAS then 
recruits the inactive serine/threonine Raf (MAPKKK) from the cytosol to the plasma 
membrane and activates it (117,118). Subsequently, activated Raf phosphorylates and 
activates MEK1/2 (MAPKK), a dual specificity tyrosine and serine/threonine kinase 
which in turn catalyze the activation of serine/threonine kinase ERK1/2 (MAPK). 
Activated ERK1/2 subsequently phosphorylates transcription factors and cytosolic 
proteins such as p90 ribosomal S6 kinase (Rsk) (119-121). Figure is modified and 
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The PI3Ks belong to a conserved family of lipid kinases that 
phosphorylates the 3’-hydroxyl group of phosphoinositides. Similar to the 
MAPK signaling pathway, the PI3K cascade responds to a variety of extra- 
and intracellular signals that regulates cellular proliferation, cell death and 
cytoskeletal rearrangements. In the recent years, the PI3K signaling pathway 
has been widely believed to play a major role in cancer and is recognized as 
one of the most frequently targeted signaling pathways in most sporadic 
tumours in humans (116,123). Interestingly, only class I PI3Ks are involved in 
cancer; there are to date, no data linking class II PI3Ks or class III PI3K to 
oncogenesis (124). This finding may reflect the different product and substrate 
specificities of the three classes of PI3K. Notably, only class I PI3Ks uses 
phosphatidylinositol 4,5-bisphosphate (PIP2) to generate  phosphatidylinositol 
3,4,5-triphosphate (PIP3), class II PI3Ks produce the 3,4-bisphosphate and the 
3-monophosphate of inositol lipids and class III can only make the 3-
monophosphate (124). The activation and overall effect of the PI3K signaling, 
as illustrated in Fig 1.12, enhances the stimulation of cellular replication and 
survival and to reduce growth inhibition and apoptosis (124).  
Notably, phosphorylation is one of the main mechanisms that directly 
regulate the protein stability and function of many pro-apoptotic and anti-
apoptotic members of the Bcl-2 family (69). For instance, it was reported that 
AKT, a serine/threonine protein kinase downstream of PI3K, binds to and 
phosphorylates Bad at serine 136 residue (125,126). Upon phosphorylation, 
Bad dissociates from anti-apoptotic Bcl-xL and is bound and sequestered in 
the cytosol by 14-3-3 proteins thereby suppressing apoptosis and promoting 
cell survival (127). In another study, it was reported that anti-apoptotic protein, 
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Mcl-1 is phosphorylated by glycogen synthase kinase-3 (GSK-3) another key 
down-stream kinase of PI3K, at serine 159 residue (128). Notably, 
phosphorylation of Mcl-1 results in its poly-ubiquitination and the consequent 
degradation via the UPS (128). Similarly, it was demonstrated that ERK1/2 
phosphorylation of Bcl-2 at serine 70 serine stabilizes Bcl-2:Bax interaction, 
thereby mediating cell survival by quenching the pro-apoptotic function of 
Bax (129). 
 
Figure 1.12 Schematic representation of PI3K signaling cascade. PI3Ks are 
heterodimers that comprise of catalytic (p110) and regulatory (p85) subunits. 
Following ligands binding at the extracellular receptors, the phosphorylated receptors 
sequester the regulatory subunit of PI3Ks, freeing the catalytic subunit to catalyze the 
phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3) (130). PIP3 is the main propagator for 
the PI3K cascade and its production is mostly deterred by phosphatase and tensin 
homolog (PTEN) which hydrolyzes PIP3 to PIP2, terminating the PI3K signaling 
(131). Tumor suppressor PTEN has been shown to be frequently inactivated or 
silenced in many caners. PIP3 then binds to pleckstrin homology (PH) domains of 
proteins such as phosphoinositide-dependent kinase 1 (PDK1) resulting in the 
membrane localization of PDK1 (130,131). PDK1 then recruits serine-threonine 
kinase AKT to the membrane. Phosphorylation and consequent activation of AKT 
then results in the activation of a range of downstream targets in the nucleus and 
cytosol (130,131). Signals originating from AKT proceeds through the tuberous 
sclerosis complex (TSC), Rheb (Ras homolog enriched in brain) and mTOR (target of 
rapamycin) ultimately, resulting in increased cellular growth and survival. Figure is 
modified and adapted from (132). 




1.3.3.1 Protein acetylation, a relatively new protein regulatory mechanism  
Protein acetylation is a reversible and highly regulated PTM first 
discovered on histones in 1968 (133) but the enzymes responsible for the 
acetyl group addition to or removal from target proteins known as histone 
acetyltransferases (HATs) and histone deacetylases (HDACs), respectively 
were not identified until 1995 (134). In the past decade, tremendous work 
investigated on protein acetylation has led to better understanding of this PTM, 
with targets rapidly expanding from histones to transcription factors, 
metabolic enzymes and signaling regulators in the cytosol (135). Notably, 
protein acetylation is now believed to be one of the most common covalent 
modifications of eukaryotic proteins (136). In fact, it has been argued that the 
frequency and importance of acetylation might actually rival phosphorylation 
as a crucial post-translational modification with as many as 50%-80% of 
proteins reportedly modified with acetylation (106,136,137). Moreover, 
comparative analyses showed that acetylation sites are significantly more 
conserved than phosphorylation sites (138). Since lysine acetylation results in 
the loss of positive charge at lysines, it strongly modulates the electrostatic 
properties (139). As such, the functional consequences may vary with the 
relative position of specific lysine residues within the protein and may 
influence the subcellular localization, activity, transcriptional activity, protein 
stability and protein-protein interaction of the targeted protein (137,139-142).  
Notably, among these cellular functions, the regulation of protein 
stability by acetylation has emerged as a general phenomenon involving 
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different functional groups of proteins (143). The fundamental relationship 
between protein acetylation and ubiquitination is the nature that both PTMs 
target lysine residues on proteins (143). Besides acetylation and ubiquitination, 
lysines are the target of additional PTMs, including sumoylation and 
methylation which may all compete with each other for one targeted lysine. A 
prior lysine acetylation could affect subsequent protein ubiquitination and vice 
versa. In fact, two main mechanisms involving the regulation of protein 
stability following lysine acetylation have been proposed (Fig 1.13) (143). 
Hence, similar to phosphorylation, protein acetylation may serve as an 
important regulator of various cellular functions including protein 
ubiquitination. 
 
Figure 1.13 Two main proposed mechanisms that may regulate protein stability 
following lysine acetylation on protein residues. (A) Competition-based protein 
stability. Since lysines are sites of both ubiquitination and acetylation, acetylation of 
lysine residues may block their ubiquitination and degradation, leading to the 
stabilization of the protein. Conversely, deacetylases (HDACs) would remove the 
acetyl moiety, freeing the lysine residue for ubiquitination and the subsequent 
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degradation by the UPS. Similarly, acetylases (HAT) and deubiquitinases (USP) 
would ensure the stability of the de-ubiquitinated proteins by protecting the target 
lysines from the E3 ubiquitin ligases. (B) (i) Acetylation of a specific lysine residue 
may create a binding site for the recruitment of an E3 ubiquitin ligase resulting in its 
poly-ubiquitination and degradation of the protein. (ii) Conversely, an acetylated 
lysine may mask the targeted lysine residues, thereby protecting them from being 
ubiquitinated. Figure is modified and adapted from (143) . 
 
1.3.3.2 Sirtuin family of deacetylases 
Present knowledge in this field suggests that the fine balance between 
HATs and HDACs provides a key contribution to the modulation of protein 
acetylation and hence the regulation of many cellular functions (135). HATs 
are grouped into two main families, HAT-A and HAT-B, depending on the 
mechanism of catalytic action and on cellular localization (135). HAT-A 
family of proteins such as HIV type 1-interacting protein (TIP60) are localized 
in the nucleus where they transfer the acetyl group from acetyl-coenzyme A 
(acetyl-CoA) to an epsilon-amino group of histone after the assembly into 
nucleosomes. On contrary, members of HAT-B family act in the cytosol and 
transfer the acetyl group from acetyl-CoA to an epsilon-amino group of free 
histones prior to their deposition on the DNA (135). Conversely, HDACs can 
be classified into four main groups in relation to their phylogenetic 
conservation (144). While classes I, II and IV encompass the classical family 
of zinc-dependent HDACs, class III comprises of the nicotinamide adenine 
dinucleotide (NAD
+
)-dependent sirtuin family of proteins (145,146).  
Founded by the yeast Sir2 (147), the sirtuin protein family represents a 
promising new class of protein deacetylases which have been linked to life-
span regulation, cell survival, apoptosis, gene expression, DNA repair and 
metabolic process regulation (146). In humans, seven sirtuins isoforms, 
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SIRT1-7 have been identified which share a common catalytic core domain 
comprising approximately 200-275 amino acids but also possess distinct N- 
and C- terminal extensions (Fig 1.14). The catalytic core domain elicits 
NAD
+
-dependent deacetylase and/or ADP-ribosyl transferase, demalonylase 
and desuccinylase activities, giving each sirtuin a characteristic enzymatic 
activity (148). With the exception of SIRT4, the sirtuin family proteins 
hydrolyze one NAD
+
 for each acetyl group removed from the substrate, along 
with the release of the nicotinamide moiety (149). The acetyl group is 
transferred to ADP-ribose to form a novel O-acetyl-ADP-ribose product (150) 
which has been proposed to serve as a secondary messenger (151). Notably, 
SIRT4 is the only sirtuin member that exhibits no histone deacetylase activity 
(152). In addition, it was revealed that SIRT5 is also capable of removing 
acyl-groups from malonylated or succinylated substrate peptides, thereby 
forming O-malonyl-ADP-ribose or O-succinyl-ADP-ribose respectively 
(153,154). Furthermore, SIRT4 and SIRT6 were shown to catalyze the transfer 
of ADP-ribose from NAD
+
 to substrate proteins (152,155). These findings 
provide evidence that sirtuins may be able to function in more than one 
biochemical reaction.  
In addition to their distinct enzymatic activities, the seven mammalian 
sirtuins are also localized in different sub-cellular compartments. Being 
localized in the nucleus, SIRT1 deacetylates several lysine residues of histones, 
including acetylated lysines 9 of histones H3 (H3K9ac), H3K14ac, H4K16ac 
and H1K26ac (156,157). SIRT1 also targets and deacetylates non-histone 
proteins and its activity may be influenced by its ability to shuttle between 
nuclear and cytosolic compartments (158,159). For instance, SIRT1 also 
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deacetylates and activates the transcriptional co-activator PGC-1α, a key 
regulator of mitochondria biogenesis (160). Over the years, it is becoming 
apparent that SIRT1 is intimately involved in the regulation of a wide range of 
cellular processes such as lipid and glucose metabolism, aging and stress 
response. Of which, the AMP-activated protein kinase (AMPK)-SIRT1 
signaling axis is of particular interest. AMPK functions as an energy sensor 
that is activated in response to cellular metabolic stress including calorie 
restriction (161). As such, it is not surprising then that SIRT1 knockout mice 
are found to have a high prenatal or early post-natal death rate (162,163).     
 
 
Figure 1.14 Schematic overview of human sirtuins, their enzymatic activity and 
sub-cellular localization. The seven mammalian sirtuins share a conserved catalytic 
domain of 200-275 amino acids (aa) and possess zinc-binding domain (indicated in 
gold and black respectively).  In contrast to the conserved catalytic domain, the 
sirtuins differ in sequence and length of their C- and N-terminal extensions. Figure is 
modified and adapted from (164). 
 
SIRT2 is the only human sirtuin which is pre-dominantly localized in 
the cytosol, but it may also be present in the nucleus where it selectively 
deacetylate histone H4K16 (165). Notably, human SIRT2 is expressed in two 
isoforms; variant 1 comprises of 389 amino acids while variant 2 does not 
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have the first 37 N-terminal amino acids and hence is consists of 352 amino 
acids (166). In the cytoplasm, SIRT2 shares α-tubulin deacetylase activity 
with histone deacetylase 6 (HDAC6) and has been proposed as the key 
microtubule deacetylase in neurons (167). Moreover, SIRT2 binds to 14-3-3 
which is involved in controlling a variety of signaling molecules such as 
kinases and phosphatases (168). The SIRT2:14-3-3 interaction enhances AKT-
dependent deacetylation of p53 by SIRT2, thereby down-regulating the 
transcriptional activity of p53 (168). These findings suggest a novel regulation 
of p53 mediated by SIRT2 alongside the well-characterized Mdm2-mediated 
regulation. 
SIRT3-5 are also referred to as ‘mitochondrial sirtuins’ due to their 
exclusive subcellular localization. SIRT3 is the primary deacetylase in the 
mitochondria where it regulates oxidative phosphorylation, protein synthesis 
and the cellular response to oxidative stress and calorie restriction (156). 
Indeed, SIRT3 knockout mice showed increased susceptibility to oxidative 
stress and metabolic damage after high fat feed (169). SIRT4 resides as a 
soluble protein in the mitochondrial matrix (152). While SIRT4 exhibits no 
histone deacetylase activity, it functions as an efficient ADP-ribosyltransferase 
(152). Notably, it was shown that SIRT4 ADP-ribosylates and deactivates 
glutamate dehydrogenase (GDH) which is required to promote the metabolism 
of glutamate and glutamine to generate ATP, thereby promoting the secretion 
of insulin (170). Knockdown of SIRT4 in insulinoma cells activates GDH, 
leading to increased amino-acid-stimulated insulin secretion (170). Moreover, 
GDH from SIRT4 knockout mice is resistant to phosphodiesterase, an enzyme 
that cleaves ADP-ribose, suggesting the absence of ADP-ribosylation on GDH 
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(170). These findings demonstrate that SIRT4 plays a role in beta cell 
mitochondria to suppress the activity of GDH by ADP-ribosylation, thereby 
repressing amino acid-stimulated insulin secretion. In addition to its 
pronounced demalonylase and desuccinylase activity (171), SIRT5 was shown 
to deacetylate and activate carbamoyl phosphate synthetase 1 (CPS1), an 
enzyme which catalyzes the initial step of the urea cycle for ammonia 
detoxification and disposal (172). Indeed, SIRT5 knockout mice failed to up-
regulate the activity of CPS1 during fasting (172). These results indicate that 
SIRT5 plays an important role in ammonia detoxification and disposal by 
deacetylating and activating CPS1.  
SIRT6 is a nuclear, chromatin-associated protein which promotes 
resistance to DNA damage and represses genomic instability in mouse cells 
(173,174). In comparison to the other sirtuins knockout mice, SIRT6 knockout 
mice displayed a severe phenotype. SIRT6 knockout mice are small and at 2-3 
weeks of age develop severe metabolic defects (174). Eventually, these mice 
will die at four weeks of age due to degenerative processes of multiple organs 
(174). In addition, the importance of SIRT6 for telomere maintenance and 
genome stabilization has also been documented (175). These findings 
demonstrate the importance of SIRT6 in DNA repair and thus in the 
maintenance of genomic integrity. Out of the seven human sirtuins, SIRT7 is 
thus far the least studied. It is a nuclear protein that is predominantly localized 
in the nucleoli where it associates with and up-regulates the rDNA 
transcription (176-179). Knockdown of SIRT7 in human cancer cell-lines 
suppresses cell proliferation and induces apoptosis, suggesting that SIRT7 
may be required for cancer cell viability (177). In addition, SIRT7 was found 
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to deacetylate and inactivate p53 (180). Notably, SIRT7 knockout mice are 
viable but suffer from progressive heart hypertrophy, accompanied by 
inflammation and decreased stress resistance, possibly a consequence of 
altered p53 activity.   
 
1.3.4 PTM regulation of MOAP-1  
Characterization study done by our laboratory has shown that MOAP-1 
is a short-lived protein with a half-life of approximately 25 minutes and is 
constitutively degraded by the UPS under non-apoptotic conditions (67). 
Interestingly, multiple apoptotic stimuli stabilize MOAP-1 through inhibition 
of its ubiquitination-mediated degradation process (67). Furthermore, it was 
showed that post-translational mechanism instead of transcriptional or 
translational mechanisms plays a significant role in mediating the stabilization 
of MOAP-1 under apoptotic conditions (67). TRIM39, a member of the 
RBCC/TRIM family (briefly discussed in Section 1.3.1) was the first regulator 
of MOAP-1 protein stability identified. TRIM39 was found to interact with 
and stabilize MOAP-1 by inhibiting its poly-ubiquitination process thereby 
reducing the degradation of MOAP-1 by the UPS (103). In agreement with its 
effect on enhancing MOAP-1 protein stability, TRIM39 sensitizes cells to 
ETOP-induced apoptosis while the loss of function analysis showed that 
knockdown of TRIM39 reduces the sensitivity of the cells to ETOP-stimulated 
apoptosis (103). In addition, elevation of MOAP-1 protein levels by over-
expression of TRIM39 promotes Bax-mediated cytochrome c release in 
isolated mitochondria (103). Three years later in 2012, it was revealed by 
another group that MOAP-1 is a novel substrate of anaphase-promoting 





) E3 ubiquitin ligase and that TRIM39 stabilized MOAP-
1 by inhibiting APC/C
Cdh1
 and consequently the APC/C
Cdh1
-mediated 
ubiquitination of MOAP-1 which prevents the degradation of MOAP-1 by the 
UPS (104). However, the precise mechanism of the inhibition of APC/C
Cdh1
 
by TRIM39 is still unknown.  
Thus far, the only PTM regulation of MOAP-1 identified is 
ubiquitination whereby poly-ubiquitination of MOAP-1 will result in its 
degradation by the UPS. Apoptotic stimuli and over-expression of TRIM39 
have been showed to inhibit the poly-ubiquitination of MOAP-1 thereby 
reducing its degradation by the UPS. However, it is highly conceivable that 
the molecular regulation of MOAP-1 is linked to a highly orchestrated cascade 
of ubiquitination/de-ubiquitination events that are intermingled with 
phosphorylation/de-phosphorylation, acetylation/deacetylation and other post-
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1.4 OBJECTIVES OF STUDY 
Bax has been shown to be a critical and essential effector for the 
mitochondrial-mediated apoptosis pathway (62-64). MOAP-1 was cloned as a 
binding partner of Bax and knockdown analysis of MOAP-1 has been shown 
to deter proper functioning of Bax thereby resulting in dramatic resistance of 
cancer cells to multiple apoptotic stimuli (65,66). Since levels of MOAP-1 has 
been demonstrate to modulate the sensitivity of cancer cells to Bax-mediated 
apoptosis, the investigation on the molecular regulation of MOAP-1 may lead 
to the identification of potential targets to elevate levels of MOAP-1 in cancer 
cells, thereby ensuring optimal Bax functioning and consequently increasing 
the sensitivity of cancer cells to chemo-therapeutic treatments. Thus, the 
doctoral research aims to investigate post-translational regulatory mechanism 
of MOAP-1.  
To achieve the aim, the following objectives are set: 
1. To evaluate close homologues of TRIM39 that may potentially act as E3 
ubiquitin ligase of MOAP-1 
2. To investigate the role of phosphorylation as a possible mechanism for 
regulating the protein stability and function of MOAP-1 
3. To evaluate sirtuin family of deacetylases as novel interactors and 
regulators of MOAP-1 





































Materials and antibodies with their suppliers are enlisted in Table 2.1 
and Table 2.2 respectively. Plasmids used in this study were enlisted in Table 
2.3.  
Table 2.1 List of materials 
Material Supplier 
Acetone Merck  
Acrylamide/bis-acrylamide 30% solution 37:1:1 Bio-Rad  
Agarose Invitrogen  
Ammonium persulfate (APS) Sigma Aldrich  
Ampicillin Sigma Aldrich  
Adenosine 5'-triphosphate (ATP) Sigma Aldrich  
β-mercaptoethanol Bio-Rad  
Bovine serum  albumin Sigma Aldrich  
Bradford dye reagent Bio-Rad  
Bromophenol blue Sigma Aldrich  
CL-Xposure® X-ray films Thermo Scientific  
Commassie Brillant blue R-250 Bio-Rad  
Cycloheximide Sigma Aldrich  
Dimethylsulfoxide (DMSO) Sigma Aldrich  
DJNK1 (JNK inhibitor) Enzo Life Sciences  
DMEM medium (high glucose) Sigma Aldrich  
DpnI New England Biolabs 
Ethanol Merck  
Ethylenediamine tetracetic acid (EDTA) Sigma Aldrich  
Etoposide Sigma Aldrich  
Fetal bovine serum (FBS) Sigma Aldrich  
Glutathione-Superflow™ Resin Clontech  
Glycerol Invitrogen  
Glycine Bio-Rad  
HEPES Sigma Aldrich  
HotStarTaq Plus DNA polymerase Qiagen 
LB Broth Sigma Aldrich  
L-glutamine GIBCO   
Lipofectamine 2000 Invitrogen  
Isopropyl beta-thiogalactoside (IPTG) Invitrogen 
LY294002 (PI3K inhibitor) Sigma Aldrich  
Methanol Fisher Scientific  




Nitrocellulose membrane Bio-Rad  
Nonidet P-40 (NP-40) Sigma 
PD98059 (MEK inhibitor) Calbiochem  
Penicillin-Streptomycin  Sigma Aldrich  
Pfu DNA polymerase  Promega 
Phenylmethylsulfonyl fluoride (PMSF) Sigma Aldrich 
Phosphate buffered saline 1
st
 Base  
PhosSTOP Phosphatase Inhibitor Cocktail Tablets Roche Diagnostics  
PI-103 (dual inhibitor of PI3K and mTOR) Cayman Chemical 
Polyvinylidene difluoride membrane (PVDF) PerkinElmer  
Ponceau S Sigma Aldrich 
Precision Plus Protein™ All Blue Standards Bio-Rad  
Protease inhibitor cocktail tablets Roche Diagnostics  
Protein A Sepharose beads Roche Diagnostics 
Qiaprep miniprep spin kit Qiagen 
Q Sepharose Fast Flow GE Healthcare 
Rapamycin (mTOR inhibitor) Santa Cruz  
Reduced glutathione Sigma Aldrich 
Restore Western Blot Stripping Buffer Thermo Scientific 
SB203580 (p38 inhibitor) Cell Signaling 
Sodium bicarbonate AnalaR Normapur 
Sodium chloride Sigma Aldrich  
Sodium dodecyl sulfate (SDS) Merck  
Sodium hydroxide Merck  
Sodium pyruvate GIBCO  
SP Sepharose Fast Flow GE Healthcare 
SuperSignal West Pico Chemiluminescent Substrate Thermo Scientific  
SYBR Safe DNA gel stain Molecular Probe  
N,N,N’,N’-tetramethylene ethyldiamine (TEMED)  Sigma Aldrich  
TNF-related apoptosis-inducing ligand (TRAIL) PeproTech Inc.  




Triton X-100 BDH   
Trypsin/EDTA (1x) GIBCO  
Tween 20  Sigma Aldrich  
U0126 (MEK inhibitor)  Promega  
X-ray developer  Konica Minolta  
X-ray fixer  Konica Minolta  
Wortmannin (PI3K inhibitor) Sigma Aldrich  
Z-Leu-Leu-Leu-al (MG132) Sigma Aldrich  
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Table 2.2 List of antibodies 
Primary Antibody Species Supplier 
Working 
Concentration 
Bax (2D2) Mouse Sigma-Aldrich 1:1000 
Bax (N20) Rabbit Santa Cruz 1:1000 
Cleaved Caspase 7 Rabbit Cell Signaling  1:1000 
ERK Rabbit Cell Signaling  1:1000 
FLAG (M2) Mouse Sigma-Aldrich 1:5000 
HA (F7) Mouse Santa Cruz 1:1000 
HA (Y11) Rabbit Santa Cruz 1:1000 
HSP60 Mouse Sigma-Aldrich 1:5000 
Mcl-1 (S19) Rabbit Santa Cruz 1:1000 
MOAP-1 Rabbit Sigma-Aldrich 1:1000 
MYC (9E10) Mouse Santa Cruz 1:1000 
MYC (A14) Rabbit Santa Cruz 1:1000 
Phospho-ERK 
(Thr202/Tyr204) Mouse Cell Signaling  1:1000 
SIRT1 Mouse Sigma-Aldrich 1:1000 
SIRT2 Mouse Sigma-Aldrich 1:1000 
Ubiquitin (P4D1) Mouse Santa Cruz 1:1000 
Secondary Antibody Species Supplier 
Working 
concentration 
Horse radish peroxidase Mouse GE Healthcare 1:5000 
Horse radish peroxidase Rabbit GE Healthcare 1:5000 
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Table 2.3 List of plasmids 




PXJ-HA-PNMA4/ HA-MOAP-1 Mammalian 




pCMV6-MYC-FLAG-TRIM11 WT Mammalian 
pCMV6-MYC-FLAG-TRIM11 C16,19A, Mammalian 




pGEX-4T1-TRIM11 WT Bacterial 
pGEX-4T1-TRIM11 C16,19A Bacterial 
pGEX-4T1-TRIM11 C31A,H33A Bacterial 
Plasmids used in Chapter 4 Expression 
PXJ-FLAG-MOAP-1 Mammalian 
PXJ-HA-MOAP-1 WT Mammalian 
PXJ-HA-MOAP-1 S27,29,31A Mammalian 
PXJ-HA-MOAP-1 S27,29,31D Mammalian 
PXJ-HA-MOAP-1 S169,173A Mammalian 
PXJ-HA-MOAP-1 S169,173D Mammalian 
PXJ-HA-MOAP-1 S27,29,31,169,173A Mammalian 
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2.2 MAMMALIAN CELL CULTURE AND DRUG TREATMENT 
2.2.1 General cell culture and maintenance  
Cell culture procedures were performed in a class II biological safety 
cabinet. HEK293T (human embryonic kidney cell-line) and HeLa (human 
cervical adenocarcinoma cell-line) cells were maintained in DMEM medium 
containing 4500 mg/L glucose, 3.7 g/L sodium carbonate, 100 mg/L sodium 
pyruvate, 100 units/ml penicillin, 1 µg/ml streptomycin and 10% v/v heat-
inactivated fetal bovin serum (FBS). For heat inactivation, FBS was incubated 
in a water bath at 55 
o
C for 1 h. Cells were sub-cultured once they were 80-90% 
confluent. Both HEK293T and HeLa cells were cultured in 100-mm plates. 
For sub-culturing, spent culture medium in the plate was aspirated and the cell 
mono-layer was rinsed with 1x PBS solution. To detach cells from the plate 
surface, 1 ml of Trypsin/EDTA 1x solution was applied onto the cell 
monolayer and the plate was incubated at 37 
o
C for 1-2 min until the cells had 
detached. Cells were re-suspended in fresh medium and sub-cultured in ratio 
ranging from 1:3 to 1:6 into new 100-mm plates. All cells were maintained at 
37°C in a humidified atmosphere of 95% air and 5% CO2 with CO2 incubator 
(Thermo Forma Series 2). For cell maintenance, cells were not cultured for 
more than 20 passages to minimize phenotypic alterations.   
2.2.2. Cell freezing and thawing 
To detach cells from the plate surface, the medium was aspirated and 
the cell monolayer was rinsed with 1x PBS solution. 1 ml of Trypsin/EDTA 
1x solution was applied onto the cell monolayer and the plate was incubated at 
37 
o
C for 1-2 min until the cells had detached. Trypsinization was stopped by 
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addition of DMEM containing 10% FBS and penicillin streptomycin. Cells 
were centrifuged at 1,200 rpm for 5 min. The supernatant was aspirated and 
the cell pellet was re-suspended in 500 µl of pre-sterilized (using a 0.20 µm 
filter] cell freezing medium containing 10% DMSO, 50 % FBS and 40 % 
DMEM. Cells were transferred to a Nalgene® cryogenic vial (CORNING) 
and frozen at -80 °C. For long-term storage, the cryogenic vial was transferred 
into a liquid nitrogen storage tank. To thaw cells, the vial was incubated at 
37 °C for 1 min, and the cell resuspension was added to 2 ml of DMEM 
containing 10 % FBS and penicillin streptomycin, followed by centrifugation 
at 1,200 rpm for 5 min. The supernatant was discarded, and the cell pellet was 
resuspended in 10 ml of culture medium and plated in a 100-mm culture dish. 
2.2.3 Preparation of drug stocks and usage of drugs 
All compounds used were weighed accurately and dissolved in DMSO 
or water to prepare the appropriate stock solutions. Drug stocks were aliquoted 
into 20 μl per tube and stored at -20 oC for usage. Proteasome inhibitor 
MG132 was used at a final concentration of 10 μM while DNA-damaging 
agent, Etoposide (ETOP) was used at a final concentration of 100 μM. TNF-
related apoptosis-inducing ligand (TRAIL) was used at concentrations ranging 
from 25 to 100 ng/ml. 100 μg/ml cycloheximide was used to block new 
protein synthesis in HEK293T.  
For the kinase inhibitors treatment, HEK293T cells were seeded in 6-
well plates approximately 24 h before treatment and cells were allowed to 
grow until 70-80% confluency. To study the effect of the kinase inhibitors on 
the up-regulation of MOAP-1 by ETOP, cells were pre-treated with various 
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kinase inhibitors and then treated with 100 μM ETOP for 16 h followed by 
analysis by western blotting. Kinase inhibitors were added to cells at doses 
and times specified in the figure legends. 
2.2.4 Transient transfection 
Cells were seeded in appropriate dishes approximately 24 h before 
transfection. Cells were allowed to grow until 60-70% confluency. 
Lipofectamine 2000 was used as the transfection reagent at a ratio 1 µl 
Lipofectamine 2000: 1 µg of plasmid DNA. In two separate tubes, the 
appropriate volume of Lipofectamine 2000 and plasmid DNA was diluted in 
serum-free medium and incubated at room temperature for 5 min. The two 
solutions were mixed and incubated for another 20 min at room temperature to 
allow the formation of DNA-liposome complexes. The transfection mixture 
was then added drop-wise into the culture medium. 6 h after the transfection, 
culture medium containing the transfection mixture was removed and the cells 
were incubated in complete growth medium for another 24-48 h before 
harvesting for western blotting analysis.  
2.2.5 Transient knock-down of TRIM11 using siRNAs 
The following GeneSolution siRNAs of human TRIM11 (catalogue 
number 1027416) was purchased from Qiagen, 
Product name  Target sequence 
1. Hs_TRIM11_1  AGAGTAGATGTCCTATAATAA 
2. Hs_TRIM11_2  AAGAATTAGGAGGCAGCCATA 
3. Hs_TRIM11_3  CAGGGAGAACGTGAACAGGAA 
4. Hs_TRIM11_4  CAGAGAGTAGATGTCCTATAA 
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100 μl of sterile RNase-free water was added to each tube containing 1 
nmol lyophilized siRNA to obtain a stock solution of 10 μM solution and 
stored at -20 
o
C until transfection. Lipofectamine 2000 was used as the 
transfection reagent at a ratio 2 µl Lipofectamine 2000: 10 nM siRNA. siRNA 
transfection was carried as described in Section 2.2.3. The final working 
concentrations of siRNAs used were 10-20 nM and cells were harvested 72 h 
after transfection for analysis.  
 
2.3 PROTEIN METHODOLOGY 
2.3.1 Cell lysate preparation, immuno-precipitation and Bradford assay  
Culture medium was aspirated and cells were rinsed in ice-cold 1x 
PBS solution containing 1 mM CaCl2 and 0.5 mM MgCl2. PBS was then 
aspirated. For direct western blotting analysis, cells were lyzed on ice in RIPA 
buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.2, 1% deoxycholate, 1% Triton 
X-100, 2 mM EDTA pH 8.0, 0.1% SDS) supplemented with protease inhibitor 
cocktail for 30 min. For co-immuno-precipitation experiments, cells were 
lyzed in immuno-precipitation (IP) lysis buffer (250 mM NaCl, 50 mM 
HEPES, 5 mM EDTA, 1% Triton X-100, 1% NP40, pH 7.4) supplemented 
with protease inhibitor cocktail for 30 min on ice. While for immuno-
precipitation of activated Bax, cells were lyzed in CHAPS lysis buffer (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1% CHAPS) 
supplemented with protease inhibitor cocktail for 30 min on ice. Whole cell 
lysate was centrifuged at top speed 13,200 rpm for 10 min. After centrifuged, 
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the protein concentration in the supernatant was estimated by using the 
Bradford protein assay reagent.  
In a 96-well plate, 2 μl of cell lysate was added to 198 μl of Bradford 
reagent and absorbance was measured at 595 nm using a UV/Visible 
spectrophotometer (Tecan). Readings were measured in triplicates for each 
sample and mean absorbance was determined. A standard plot was obtained 
for a range of BSA concentrations (0.1-2 μg/ml). Protein concentrations in cell 
lysates were then calculated based on the linear equation derived from the 
standard plot. Total cell lysates containing equal amount of proteins were 
rotated with appropriate antibodies (normally, 1-2 µg) for 4 hour at 4 
o
C, 
followed by incubation with Protein A agarose beads for 2 hour.  The beads 
were washed with an appropriate buffer for at least 5 times. 20 μl of 5X SDS 
loading buffer (200 mM Tris-HCl, pH 6.8, 8% SDS, 4% β-mercaptoethanol, 
40% glycerol, 50 mM EDTA, 0.08% Bromophenol blue) was added to the 
beads and heated at 100 
o
C for 5-10 min. Total cell lysates and precipitates 
were resolved using sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). 
2.3.2 SDS-PAGE gel electrophoresis 
Proteins contained in the cell lysates were separated using SDS-PAGE. 
Resolving gels containing 10 or 13.5% w/v acrylamide and stacking gels 
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Table 2.4 Formulae for resolving and stacking gel solutions for 4 SDS-PAGE 
gels 
 
All reagents required for resolving gel were mixed and approximately 
30 ml of the resolving gel solution was quickly poured into four casting 
cassettes. An overlay of methanol was applied onto the surface of the gel 
solution. The gel was allowed to polymerize for about 20 min after which the 
layer of methanol was discarded. Stacking gel solution was then poured over 
the resolving gel contained in the casting cassette. A 10- or 15-well comb was 
inserted immediately into the stacking gel solution to create wells for loading 
samples and allowed to polymerize for 20 min. For both resolving and 
stacking gels, APS and TEMED were added immediately before pouring the 
solution in the casting assembly to avoid premature polymerization. Once the 
stacking gel had polymerized, the comb was removed and the gel along with 
the casting cassette was placed in an electrophoresis tank containing running 
buffer. Proteins were separated at a constant voltage of 80 V for 
approximately 2 hour in a running buffer consisting of 25 mM Tris-HCl, 192 
mM glycine and 0.1% SDS. After separation, the proteins were transferred 
onto nitro-cellulose membranes under constant voltage of 100 V for 
approximately 2 hour in an ice-cold transfer buffer consisting of 25 mM Tris-
HCl, 192 mM glycine and 20% v/v methanol. The proteins on the gel were 
Ingredient 
Resolving gel solution 4% Stacking    
gel solution 10% 13.50% 
dH2O (mL) 12 8.5 6.1 
Tris (mL) 7.5 (1.5 M, 
pH 8.8) 
7.5 (1.5 M, 
pH 8.8) 
2.5 (0.5 M,  
pH 6.8) 
30% Acrylamide (mL) 10 13.5 1.3 
10% SDS (µL) 300 300 100 
10% APS (µL) 200 200 50 
Temed (µL) 20 20 10 
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directly stained with Ponceau S and the membranes were washed with PBST 
(137 mM NaCl, 3 mM KCl, 25 mM Tris HCl pH 7.4 containing 0.1% v/v 
Tween 20) before proceeding with western blotting.  
2.3.3 Western blotting 
The transblotted membrane was blocked with 5% fat-free milk in 
PBST for 1 hour at room temperature followed by incubation with primary 
antibody for 2 hour at room temperature or up to overnight at 4 °C with gentle 
shaking. Membranes were washed thrice with PBST every 15 min before 
incubation with corresponding secondary antibody conjugated to HRP in 5% 
milk in PBST for 1 hour at room temperature. The membranes were washed 
thrice with PBST every 15 min to remove any unbound antibody. The 
transblotted proteins of interest were detected by applying equal volumes of 
reagent 1 and 2 of the ECL system (total volume 1-2 ml) to the membranes, 
capturing the emitted chemiluminescence onto CL-Xposure® X-ray films and 
developing the films using a Konica Minolta film developer. 
2.3.4 Membrane stripping and re-probing  
For antibody stripping, the nitrocellulose membrane was incubated 
with western stripping buffer (Thermo Scientific) for 45 min at room 
temperature with gentle shaking. Membranes were then blocked in 5 % 
milk/PBST for an hour before being probed with another primary antibody. 
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2.3.5 Cycloheximide chase protein stability assay 
HEK293T cells were seeded in 12-well plates approximately 24 h 
before treatment and cells were allowed to grow until 70-80% confluency. 
Culture medium was aspirated and replaced with fresh medium containing 100 
μg/ml cycloheximide. Immediately after changing medium, the first set of 
cells were lyzed in RIPA lysis buffer supplemented with protease inhibitor 
cocktail. These samples were considered as 0 time point. This was repeated at 
1, 3 and 5 hour time-point for over-expressed MOAP-1 and 0.5, 1 and 2 hour 
time-point for endogenous MOAP-1. Whole cell lysates were assessed by 
protein estimation assay in triplicates as in Section 2.3.1. 50 μg of total protein 
were analyzed by SDS-PAGE and western blotting as described in Sections 
2.3.2 and 2.3.3. Mcl-1 was used as a positive control to ensure that the CHX 
assay worked as expected while HSP60 was used as an internal loading 
control.   
2.3.6 Expression and purification of bacterial-expressed GST-FLAG-
MOAP-1 recombinant protein 
Plasmid encoding GST-FLAG-MOAP-1 protein was transformed into 
100μl of E. coli BL21 (DE3) competent cells and the mixture was plated onto 
an ampicillin agar plate and incubated overnight at 37 
o
C. A single colony was 
picked and cultured in 10 ml Lysogeny broth (LB) containing 50 µg/ml 
ampicillin and incubated in a shaker at 37 
o
C to obtain saturated cultures. The 
saturated cultures were added to 400 ml of LB with 50 µg/ml ampicillin and 
grown for appropriate time to obtain 0.6-0.7 absorbance at 600 nm. The 
expression of recombinant proteins was induced overnight by 1 mM isopropyl 
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beta-thiogalactoside (IPTG) at 16 °C. Bacteria were harvested by 
centrifugation at 5,000 rpm for 10 min at 4 
o
C. The bacteria pellet was rinsed 
once in 50 ml ice cold PBS and centrifuged at 5,000 rpm for another 10 min. 
The bacterial pellet was then re-suspended in 30 ml of ice cold PBS 
supplemented with protease inhibitors and lyzed by sonication or French Press. 
The lysates were then clarified by centrifugation at 250,000 rpm for 1 hour at 
4 
oC. The supernatant was collected and rotated with 500 μl of pre-washed 
glutathione–Sepharose beads for 1 hr at 4oC. The beads were collected and 
washed several times with PBS. The GST-tagged protein was then eluted with 
20 mM reduced glutathione in 50 mM Tris, pH 7.9. For the generation of 
recombinant FLAG-MOAP-1 without the GST tag, the beads were incubated 
with appropriate amount of thrombin for 1 hour at 4 
o
C. Thrombin was 
inactivated by the addition of protease inhibitor, PMSF. Eluted proteins were 
dialyzed using Slide-A-Lyzer
®
 dialysis cassette in 50 mM Tris, pH 7.9 for 
overnight. The protein solution was concentrated using an Amicon Ultra-15 
Centrifugal Filter Unit (Millipore) following supplier’s protocol. The final 
protein solution was stored at -80 
o
C until usage.  
2.3.7 Indirect immuno-fluorescence  
      HeLa cells grown on cover-slips were fixed and permeabilized with 
methanol: acetone (1:1 ratio) for 30 min at 4°C. After sequentially washed 
with PBS, samples were then blocked with 1% w/v BSA in PBS for 30 min at 
room temperature. Cells were then incubated with anti-FLAG antibody (1:200 
dilution) against protein of interest (FLAG-SIRT1-5) in 0.1% w/v BSA for 1 
hour at room temperature with gentle shaking. After washing thrice with PBS 
for 15 minutes, cells were incubated with anti-mouse conjugated to Cy3 
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(1:500 dilution) for 1 hour at room temperature. Samples were washed thrice 
again at 15 min intervals to minimize non-specific binding. The plates were 
gently shaken during incubation to allow even distribution of the antibodies on 
the cover-slips. Immuno-labeled cover-slips were mounted on glass slides 
using 50% glycerol in water. Edges of the cover-slips were sealed onto the 
slide using clear nail polish. Images were obtained using confocal laser 
microscope (Olympus Fluoview FV10i Confocal Microscope, Japan).  
2.3.8 In vitro phosphorylation assay 
Recombinant GST-MOAP-1 was expressed and purified as described 
in Section 2.3.6. For the brain tissue harvest and preparation, the whole brain 
was taken out from a male mouse and homogenized in lysis buffer (25 mM 
HEPES pH 7.3, 1.5 mM MgCl2, 0.2 mM EDTA, 20 mM β-glycerophosphate, 
1 mM Na3VO4, 5% glycerol, 0.2% Triton X-100) supplemented with protease 
inhibitor in the ratio 1ml of lysis buffer to 0.1g of brain tissue. The tissue 
lysate was centrifuged for 100, 000g for 30 mins, 4 
o
C. The clarified tissue 
lysate was crudely purified using SP (cation exchanger) or Q (anion exchanger) 
Sepharose Fast Flow and eluted with 0.25M, 0.5M, 0.75M and 1M of NaCl. 
The protein concentrations of the eluates were determined with Bradford assay. 
For the collaboration with Jeff at IMCB, 5 µg purified recombinant GST-
MOAP-1 was incubated with 4 μg of brain or liver lysates and 10µM [γ-32P] 
ATP at 30 
o
C for 20 min in a kinase buffer (25 mM HEPES pH 7.3, 25 mM 
NaCl, 5 mM MgCl2, 2.5 mM NaF, 5 mM β-glycerophosphate, 0.025% Triton 
X-100). The reactions were stopped by boiling the mixtures in 2x SDS-PAGE 
sample buffer, separated on SDS-PAGE, transferred to polyvinylidene 
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difluoride membrane (PerkinElmer Life Sciences), and auto-radiographed. All 
[γ-32P] ATP radio-labeling experiments were conducted at a collaborator’s 
laboratory in IMCB, Biopolis. For the mass spectrometry collaboration with Li 
Rong at ETC, similar in vitro phosphorylation reactions were conducted as 
described above. However, ATP was used in replacement of [γ-32P] ATP. 
Phosphorylation reactions were stopped by boiling the mixtures in 2x SDS-
PAGE sample buffer, separated on SDS-PAGE. The gels were then submitted 
to the collaborator for mass spectrometry analysis.     
2.3.9 In vitro ubiquitination assay 
The ubiquitination reaction was conducted by the Prof Wong Hong 
Rui’s laboratory in Xiamen University. Briefly, the in vitro ubiquitination 
assay was conducted by incubating E1 activating enzyme, E2 conjugating 
enzyme (UbcH5C), GST-TRIM11 (as the E3 ubiquitin ligase), FLAG-MOAP-
1 (as the substrate), adenosine 5'-triphosphate (ATP) and ubiquitin in a 
reaction buffer containing 50 mM Tris, 5 mM MgCl2 and 2 mM DTT at pH 
7.5. GST-TRIM11 and FLAG-MOAP-1 were expressed and purified by GST-
pull down as described in Section 2.3.6. The reaction was incubated at 30 
o
C 
for 2 hour. For total lysates, samples were boiled in loading buffer to stop the 
reaction and subjected to SDS-PAGE and western blotting as described above. 
For the in vitro ubiquitination assay followed by co-immuno-precipitation 
assay, reaction samples were boiled in 1% SDS to terminate the reaction then 
diluted 10 times in 0.5% TNTE and precipitated with anti-FLAG antibody to 
pull down ubiquitinated-conjugated MOAP-1. Similar to total lysates, the 
precipitates were subjected to SDS-PAGE and western blotting as described 
above.   
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2.4 MOLECULAR BIOLOGY TECHNIQUES AND METHODS 
2.4.1 Plasmid DNA transformation 
Pure plasmid DNA (100-500 ng) was added into 100 µl of competent 
cells, which were pre-thawed on ice. The mixture was incubated on ice for 30 
min, heat-shocked for 45 sec at 42 °C water bath and immediately put back on 
ice for another 2 min. 1 ml pre-warmed LB was added into the mixture, 
followed by shaking at 37 °C warm room for 1 hour. The cells were pelleted 
by centrifugation at 8,000 rpm for 1 min at room temperature. Most of the 
supernatant was discarded and the cells were re-suspended in the remaining 
supernatant and spread on the LB agar plates containing the appropriate 
antibiotic and incubated overnight at 37 
o
C.    
2.4.2 Mini-preparation of plasmid DNA 
The Wizard
®
 Plus SV Minipreps DNA Purification System (Promega) 
was used for rapid isolation of small-scale plasmid DNA. The 2-4 ml 
overnight grown bacteria cultures were harvested by centrifugation for 5 min 
at 4,000 rpm and the supernatant was discarded. The pellet was completely re-
suspended in Cell Re-suspension Solution (50 mM Tris-HCl, Ph 7.5, 10 mM 
EDTA and 100 µg/ml RNase A) by vortexing, followed by the addition of 
Cell Lysis Solution (0.2M NaOH and 1% SDS). After incubation of the 
mixture for 5 min at room temperature, Alkaline Protease Solution was added, 
followed by incubation for another five minutes. The bacterial lysate was 
centrifuged at 13,200 rpm for 10 min at room temperature immediately after 
the addition of Neutralization Solution (4.09M guanidine hydrochloride, 
0.759M potassium acetate and 2.12M glacial acetic acid, pH 4.2).  The cleared 
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lysate was transferred to the Spin column and centrifuged for 1 min at 13,200 
rpm at room temperature. Column Washing Solution (162.8 mM potassium 
acetate, 22.6 mM Tris-HCl, Ph 7.5 and 0.109 mM EDTA, pH8.0) previously 
diluted with 95% ethanol was added to the Spin Column, followed by another 
centrifugation. The wash procedure was repeated once more before eluting 
DNA with 40-100 µl of distilled H2O. Concentration of the plasmid DNA was 
determined using the NanoDrop 1000 spectrophotometer (Thermo Scientific). 
All plasmids were sent for sequencing to ensure no unwanted mutations were 
introduced.  
2.4.3 Maxi-preparation of plasmid DNA 
Large-scale plasmid DNA isolation was performed by using the 
QIAGEN Plasmid Maxi Kit according to the manufacturer’s instructions. 400 
ml of overnight grown bacteria cultures were harvested by centrifugation and 
subsequently incubated with P1 (Re-suspension Buffer), P2 (Lysis Buffer) and 
P3 (Neutralization Buffer), which were similar to the procedures of mini-prep 
as described above. After centrifugation, the clear supernatant was carefully 
transferred to the pre-equilibrated QIAGEN-tip 500 column, followed by 
washing with Buffer QC (1.0M NaCl, 50mM MOPS pH 7.0 and 15% 
isopropanol). The DNA was eluted by Buffer QF (1.25M NaCl, 50 mM Tris-
HCl, pH 8.5 and 15% isopropanol) and precipitated by isopropanol. The DNA 
pellet was washed with 70% ethanol, air-dried and dissolved in 500-800 µl of 
distilled H2O. Concentration of the plasmid DNA was determined using the 
NanoDrop 1000 spectrophotometer (Thermo Scientific). All plasmids were 
sent for sequencing to ensure no unwanted mutations were introduced. 
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2.4.4 Agarose gel electrophoresis 
To pour a gel, agarose powder was mixed with TAE buffer (40 mM 
Tris-acetate and 2 mM EDTA) to the desired concentration. SYBR Safe DNA 
gel stain was added to the gel at this point to facilitate visualization of DNA 
after electrophoresis. Samples containing DNA mixed with loading buffer 
were pipetted into the sample wells. Agarose gel electrophoresis was carried 
out at constant voltage 100 V in TAE buffer. 100 bp or 1 kb DNA ladders 
(New England Biolabs) were used to determine the size of the DNA. The 
DNA bands were detected by ultra-violet (UV) illumination.  
2.4.5 Site-directed mutagenesis 
Site-directed mutagenesis was performed using the QuikChange® XL 
site-directed mutagenesis kit (Stratagene). Complementary primers were 
designed with the point mutations in the middle of the primers with 15-20 
nucleotides of correct sequence on both sides. The following is the list of 
sense and antisense primers used: 
 
1. MOAP-1 S27,29,31A 
GATTGCCGGCATCGCCCAGGCCTGCGCTGTGGCAGAAATCG (sense) 
CGATTTCTGCCACAGCGCAGGCCTGGGCGATGCCGGCAATC (antisense) 
2. MOAP-1 S27,29,31D 
GATTGCCGGCATCGACCAGGACTGCGACGTGGCAGAAATCG (sense) 
CGATTTCTGCCACGTCGCAGTCCTGGTCGATGCCGGCAATC (antisense) 
3. MOAP-1 S169,173A 
GCTGAGAGTGTTCGCGGGCAGGGAGGCTCCAGAACCAGG (sense) 
CCTGGTTCTGGAGCCTCCCTGCCCGCGAACACTCTCAGC (antisense) 
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All point mutations were made using PXJ-HA-MOAP-1 (wild type) as 
the DNA template apart from MOAP-1 S27,29,31,169,173A and MOAP-1 
S27,29,31,169,173D which were made using MOAP-1 S27,29,31A and 
MOAP-1 S27,29,31D respectively as the template. 50-100 ng of DNA 
template, 125 ng of each primer, 1 µl of dNTP mix [25 mM for each deoxy-
adenine (dATP), deoxy-cytosine (dCTP), deoxy-guanine (dGTP) and deoxy-
thymidine (dTTP) nucleotides] and 1 µl of Pfu DNA polymerase (2.5 U/µl) 
was used for each 50 µl reaction. The PCR reaction was performed by 16 
cycles of DNA denaturation at 95 
o
C for 30 sec, primer annealing at 50 
o
C for 
1 min and DNA extension at 68 
o
C for 2 min/1 kb after a pre-denaturation at 
95 
o
C for 5 min. The reaction was kept at 4 
o
C after the last cycle. The newly 
synthesized and non-methylated DNA incorporated with targeted mutant was 
obtained by addition of 1 µl of DpnI to the reaction to digest the methylated 
wide type parental DNA templates. The DNA with targeted mutation was 
transformed into DH5α E. Coli using the heat shock protocol as described in 
Section 2.4.1. Potential DNA plasmid clones were first sequenced to identify 
clones with the desired mutations. The plasmid clones with the desired 
mutations were then sequenced from end to end to ensure that no undesired 
mutations were present.   
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2.4.6 RNA extraction, cDNA preparation and quantitative Real-time PCR  
Total mRNA transcripts were extracted from HEK293T cells (transiently 
transfected with TRIM11 siRNAs as described in Section 2.2.5) using 
RNeasy
®
 Plus Minikit (Qiagen) and treated with RNase-free DNase (Qiagen) 
following the supplier’s protocol. The concentration of the total mRNA 
extracted was determined using a NanoDrop 1000 spectrophotometer (Thermo 
Scientific). Reverse transcription was performed by using Superscript First 
Strand synthesis system (Invitrogen), following the supplier’s protocol. The 
resulting cDNA was used for isolating certain genes. GAPDH was used as an 
internal control. The cDNA was then subjected to quantitative real-time PCR 
(qRT-PCR) using QIAgility (Qiagen). The following primers were used in 
qRT-PCR: 
1. TRIM11 
Forward primer: GGGAGTGTGTCCTTTGAGCA 
Reverse primer:  TGCAGGAACTGTGCAGCTTA 
2. GAPDH  
Forward primer: ATGTTCGTCATGGGTGTGAA 
Reverse primer: TGTGGTCATGAGTCCTTCCA 
 
2.5 PROTEIN ALIGNMENT TOOL 
The following online tool was used to align multiple protein sequences of 
MOAP-1 and TRIM11: 












Identification and characterization of TRIM11 as a 
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3.1 INTRODUCTION  
3.1.1 Identification of TRIM11 and TRIM21 as close homologues of 
TRIM39 
Previous members in the laboratory have reported the identification 
and characterization of TRIM39 as a binding partner of MOAP-1 (103). 
TRIM39 was found to extend the half-life of MOAP-1 through the inhibition 
of MOAP-1 poly-ubiquitination process, thereby reducing the elimination of 
MOAP-1 by the ubiquitin proteasome system (UPS). The increased protein 
level of MOAP-1 brought about by over-expression of TRIM39 sensitizes 
cells to the DNA-damaging agent, Etoposide (ETOP)-induced cell death, and 
to Bax-mediated cytochrome c release from isolated mitochondria. In a similar 
manner, the knockdown of TRIM39 leads to decreased stabilization of 
MOAP-1 as well as reduced sensitivity of the cells to ETOP-induced apoptosis. 
In a recent study, it was revealed that the influence of TRIM39 on MOAP-1 
levels stems from the ability of TRIM39 to directly inhibit APC/C
Cdh1
-
mediated protein ubiquitination of MOAP-1 (104). However, it is not yet clear 
how TRIM39 inhibits the APC/C, a multi-unit E3 ubiquitin ligase.   
Since TRIM family of proteins are generally believed that to function 
as E3 ubiquitin ligases due to the presence of the characteristic RING finger 
domain, it is conceivable that perhaps there could be a close homologous 
protein of TRIM39 that can function as an E3 ubiquitin ligase for MOAP-1. 
Hence, we decided to identify and evaluate close homologues of TRIM39 to 
assess their ability in promoting degradation of MOAP-1. To address this, we 
analyzed the phylogenetic tree of the TRIM family and identified TRIM11 and 
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TRIM21 as close homologues of TRIM39 (Fig 3.1A). Using ClustalW2, an 
online software for multiple protein sequence alignment, we demonstrated that 
human protein sequences of TRIM11 and TRIM21 share up to 40% amino 
acid identity to TRIM39 (Fig 3.1B).   
 




Figure 3.1 TRIM family of proteins. A. Phylogenetic tree analysis of the TRIM 
family of proteins. TRIM11 and TRIM21 are close homologues of TRIM39. B. 
Schematic diagram to depict full length human TRIM39, TRIM11 and TRIM21 
proteins. The TRIM family of proteins is characterized by a tripartite (also known as 
RBCC) motif that comprises a RING finger domain, a B-box and a coiled-coil 
domain at the N-terminal region (187) The C-terminus consists of the B30.2 domain 
which comprises of PRY and SPRY domains. The percentage (underlined) reflects 
the degree of homology between TRIM39, TRIM11 and TRIM21 based on their 
protein sequences. the amino acid identity to TRIM39. The amino acid residues 
which demarcate the various domains are indicated.   




3.2.1 TRIM11, but not TRIM21, down-regulates protein levels of MOAP-
1  
Since we postulate that there could be a close homologous protein of 
TRIM39 that may potentially function as an E3 ubiquitin ligase of MOAP-1, 
we first evaluated whether TRIM11 could negatively modulate the protein 
stability of MOAP-1 through the ubiquitin proteasome degradation pathway. 
To this end, we examined whether co-expression of TRIM11 and MOAP-1 
will down-regulate protein level of MOAP-1 and, if so, whether the 
proteasome inhibitor MG132 will inhibit the TRIM11-induced MOAP-1 
down-regulation. Co-expression of TRIM39 and MOAP-1 was included in this 
experiment as a control to validate the up-regulation of MOAP-1 by TRIM39. 
HEK293T cells were used due to its high transfection efficiency.  
In agreement with the results obtained previously (103), TRIM39 up-
regulated protein level of MOAP-1 under co-expression condition (Fig 3.2, 
lanes 1 and 4). On contrary, TRIM11 down-regulated MOAP-1 and 
proteasome inhibitor (lanes 2 and 4), MG132 reversed the TRIM11-mediated 
down-regulation of MOAP-1 (lanes 2 and 3). These results suggest TRIM11 
mediates the protein stability of MOAP-1 in a manner that is dependent on the 
proteasome. In addition, both MOAP-1 and TRIM11 are up-regulated by 
MG132, indicating that the protein stability of both proteins is regulated via 
the ubiquitin proteasome system (UPS).    
 





Figure 3.2 TRIM11 and TRIM39 exert opposing effect on the protein stability of 
MOAP-1. HEK293T cells are transiently transfected with HA-MOAP-1 and MYC-
FLAG-TRIM11 or MYC-FLAG-TRIM39. At 24 hour post-transfection, 10µM 
MG132 was added to the cells for 16 hours. Cells were harvested and protein samples 
were separated on SDS-PAGE and analyzed by western blotting. 50μg total cell 
lysate were loaded in each lane. HSP60 was used as a loading control.  
 
We next proceeded to check whether TRIM21 could negatively 
modulate the protein stability of MOAP-1 through the ubiquitin proteasome 
degradation pathway. To this end, we examined whether co-expression of 
TRIM21 and MOAP-1 will down-regulate MOAP-1 and, if so, whether the 
proteasome inhibitor MG132 will inhibit the TRIM21-induced MOAP-1 
down-regulation. Co-expression of TRIM11 and MOAP-1 was included in this 
experiment to validate the down-regulation of MOAP-1 by TRIM11. 
Consistent with the result obtained in Fig 3.2, TRIM11 down-regulated 
MOAP-1 (Fig 3.3, lanes 3 and 5) and MG132 reversed the TRIM11-mediated 
down-regulation of MOAP-1 (lanes 3 and 4). In contrast, over-expression of 
TRIM21 did not result in the down-regulation of MOAP-1 (lanes 5 and 9). To 
a certain extent, an up-regulation of MOAP-1 by TRIM21 could be observed 
suggesting that TRIM21 may function, similar to TRIM39, as a positive 
regulator of MOAP-1. In addition, the protein level of TRIM21 was not 
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affected by MG132 treatment, suggesting that the protein regulation of 
TRIM21 is likely not mediated through the UPS. However, since the objective 
of the study was to identify a close homologue of TRIM39 that could 
potentially function as an E3 ubiquitin ligase of MOAP-1, we decided to focus 




Figure 3.3 TRIM11, but not TRIM21, down-regulates MOAP-1 protein level 
under co-expression condition in HEK293T cells. HA-MOAP-1 was co-transfected 
with MYC-FLAG-TRIM11 or MYC-FLAG-TRIM21 in HEK293T cells. At 24 hour 
post-transfection, 10μM MG132 was added to the cells for 16 hours. Cells were 
harvested and protein samples were separated by SDS-PAGE and analyzed with 
western blotting. 50μg total cell lysate were loaded in each lane. HSP60 was used as a 
loading control.  
 
3.2.2 TRIM11 down-regulates PNMA2, PNMA4 (MOAP-1) and PNMA6 
MOAP-1, also known as PNMA4, belongs to the Paraneoplastic Ma 
antigens (PNMA) family which comprises of six members, PNMA1-6 in 
human. Notably, PNMA1-3 were first identified through screening expression 
libraries using sera from patients suffered from Paraneoplastic Neurological 
Syndromes (PNS). Whereas, MOAP-1 along with PNMA5 and PNMA6, were 
found to share high degree of amino acid sequence homology with PNMA1-3 
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(40-54% amino acid identity), indicating that they are members of the same 




Figure 3.4 MOAP-1 (PNMA) family of proteins. A. Alignment of predicted amino 
acid sequences of MOAP-1 (PNMA) family of proteins. B. Schematic to depict 
MOAP-1 family of proteins. Percentage represents amino acid identity to MOAP-1. 
Total number of amino acid for the full length protein is indicated on the right. C. 
Phylogenetic tree analysis of the MOAP-1 family of proteins.   
 
We asked if down-regulation of MOAP-1 (PNMA4) by TRIM11 is 
specific to MOAP-1. To do this, PNMA1-6 and TRIM11 were transiently co-
transfected into HEK293T cells for 48 hours. As shown in Fig, 3.5, apart from 
MOAP-1 (PNMA4), TRIM11 also down-regulates the protein levels of 
PNMA2 and PNMA6. Interestingly, other members in the laboratory have 
demonstrated that PNMA2 and PNMA6 were the only PNMA members found 
to interact with MOAP-1 (data not shown). It may suggest that PNMA2, 4 and 
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6 could exist as a complex and hence when targeted by TRIM11, all three 




Figure 3.5 TRIM11 down-regulates PNMA 2, 4 and 6 under co-expression 
condition in HEK293T cells. HEK293T cells were transiently transfected with HA-
PNMA1-6 and MYC-FLAG-TRIM11 for 48 hours. Cells were harvested and protein 
samples were separated by SDS-PAGE and analyzed with western blotting. 50μg 
total cell lysate were loaded in each lane.  HSP60 was used as a loading control. 
 
3.2.3 TRIM11 interacts with MOAP-1 
Since TRIM11 is able to down-regulate protein levels of MOAP-1, we 
next proceeded to ask if a physical association between them can be detected. 
To do so, an in vitro pull-down assay was conducted. Bacterially expressed 
FLAG-MOAP-1 was incubated with bacterially expressed GST or GST-
TRIM11. As illustrated in Fig 3.6, direct interaction between MOAP-1 and 
TRIM11 was detected. This supports the hypothesis that TRIM11 may 
function as an E3 ubiquitin ligase of MOAP-1 since direct association between 
the E3 ligase and its substrate was shown.   
 




Figure 3.6 TRIM11 interacts with MOAP-1 in vitro. Bacterially produced FLAG-
MOAP-1 was incubated with bacterially expressed GST or GST-TRIM11. Associated 
MOAP-1 and input MOAP-1 were determined by immuno-blotting with anti-FLAG 
antibody. GST and GST-TRIM11 was detected with anti-GST antibody. The asterisk 
indicates that the data was provided by a collaborator from Xiamen University.  
 
In addition, a co-immuno-precipitation assay was carried out in 
HEK29T cells over-expressing MYC-FLAG-TRIM11 and HA-MOAP-1. At 
24 hour post-transfection, 10µM MG132 was added to the cells for 16 hours. 
Cell lysates were immuno-precipitated with anti-FLAG antibody. As 
illustrated in Fig 3.7, MOAP-1 was found to interact with TRIM11 under 
MG132 treatment in vivo, further supporting the hypothesis that TRIM11 may 
function as an E3 ubiquitin ligase of MOAP-1..  
 
Figure 3.7 TRIM11 interacts with MOAP-1. HEK293T cells were transiently 
transfected with MYC-FLAG-TRIM11 and HA-MOAP-1 for 24 hours. 10µM 
MG132 was added to the cells for 16 hours. Cells were then harvested and cell lysates 
were immuno-precipitated with anti-FLAG. Cell lysates and immuno-precipitates 
were separated by SDS-PAGE and analyzed with western blotting. HSP60 was used 
as a loading control. 
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3.2.4 TRIM11 regulates MOAP-1 by modulating its protein stability 
Using the cycloheximide (CHX) chase assay, it was revealed that 
TRIM39 up-regulates MOAP-1 protein level by regulating its protein stability 
(103). We postulated that TRIM11 may regulate MOAP-1 abundance in a 
similar manner. To test this possibility, we evaluated the effect of TRIM11 on 
the half-life of MOAP-1. 100µg/ml CHX was added to HEK293T cells 
transiently over-expressing both HA-MOAP-1 and MYC-FLAG-TRIM11. 
Steady-state protein levels of HA-MOAP-1 were assessed at 1, 3 and 5 hours 
after treatment of CHX. As shown in Fig 3.8, MOAP-1 was rapidly degraded 
in cells over-expressing TRIM11 than in vector-transfected cells suggesting 
that TRIM11 down-regulates MOAP-1 level by regulating its protein stability.  
 
 
Figure 3.8 TRIM11 destabilizes MOAP-1. Cycloheximide (CHX) chase analysis of 
MOAP-1 turn-over. HEK293T cells were transfected with HA-MOAP-1 and MYC-
FLAG-TRIM11. Cells were subjected to 100µg/ml cycloheximide at 24 hour post-
transfection and harvested at the indicated time points. HSP60 was used as a loading 
control to demonstrate that equal amounts of cell lysates was added into each lane.    
 
3.2.5 RING finger domain of TRIM11 is required for TRIM11-mediated 
down-regulation of MOAP-1 
Given that TRIM11 has a RING finger domain and is a potential E3 
ubiquitin ligase of MOAP-1, we investigated the importance of the RING 
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finger domain in the down-regulation of MOAP-1 by TRIM11 since critical 
residues in the RING finger domain have been shown to be essential for 
mediating E3 ubiquitin ligase activity (189). The RING finger domain which 
comprises of a series of cysteine and histidine residues forms a 3-dimensional 
cross-braced structure held together by zinc ions, mediating protein-protein 
interactions. Substitution of cysteine and histidine residues to alanine disrupts 
the conformation of the RING finger domain leading to the loss of enzymatic 
activity and protein interaction with other proteins (104). Multiple site-
directed mutagenesis was carried out to generate two versions of human 
TRIM11 in which conserved cysteine and histidine residues at 16, 19, 31 and 
33 were substituted with alanine (Fig 3.10). It is noteworthy that all the four 
residues selected are conserved in all mammalian species examined (Fig 3.9, 
boxed in full lines). The three other conserved cysteine residues (at 36, 39 and 
43) found in the RING finger domain were not included in this study (Fig 3.9, 
boxed in dotted lines).  
 
 
Figure 3.9 Identification of conserved residues for multi-site directed 
mutagenesis. Multiple protein sequence alignment was carried using ClustalW2 
algorithm. Cysteine (C) residues at 16, 19 and 31 and histidine (H) residue at 33 were 
substituted with alanine to investigate the importance of the RING finger domain in 
the down-regulation of MOAP-1 by TRIM11 (boxed in full lines). Conserved 
cysteine residues at 36, 39 and 43 in the RING finger domain remain to be mutated in 
future work (boxed in dotted lines).  
 





Figure 3.10 TRIM11 mutants with point mutations in the RING finger domain. 
Each mutant is listed and differences from the WT sequence are indicated in bold.  
 
Mutations of the cysteine and histidine residues within the RING 
finger domain of TRIM11 seem to reduce drastically the ability of TRIM11 to 
down-regulate MOAP-1 (Fig 3.11), suggesting that these key residues in the 
RING finger domain are required for TRIM11-mediated down-regulation of 
MOAP-1. In addition, we observed that these TRIM11 cysteine mutants, 
unlike the wild type TRIM11, were more stable and MG132 had little, if any, 
effect on the stability of these TRIM11 mutants (Fig 3.11). This may suggest 
that the RING finger domain of TRIM11 may be required for its auto-
regulation by the ubiquitin proteasome system. Similar finding was reported 
for TRIM5, another member of the TRIM/RBCC family. TRIM5 mutants 
containing amino acid changes designed to disrupt the zinc binding of the 
RING finger mutant were observed to be more stable suggesting that the 
presence of an intact RING finger domain contributes to the degradation of 
TRIM5 (190).  
 




Figure 3.11 Mutation of the conserved cysteines in the RING domain of TRIM11 
loses its ability to degrade MOAP-1. HEK293T cells were transiently transfected 
with MYC-FLAG-TRIM11 WT and mutants (C16,19A and C31A,H33A). At 24 hour 
post-transfection, 10µM MG132 was added to the cells for 16 hours. Cells were then 
harvested and protein samples were separated by SDS-PAGE and analyzed with 
western blotting. 50μg total cell lysate were loaded in each lane.  HSP60 was used as 
a loading control. 
 
3.2.6 TRIM11 interacts with E2 ubiquitin-conjugating enzymes  
In some instances, it is known that the RING-type E3 ubiquitin ligase 
would need to interact with E2 ubiquitin-conjugating enzymes for mediating 
the transfer of ubiquitin from the active site of the E2 enzymes to (usually) 
lysine residues on substrate proteins (94). Thus, we asked if TRIM11, being a 
classical RING-type E3 ubiquitin ligase can interact with E2 ubiquitin-
conjugating enzymes UbcH2 and UbcH13. It was reported that UbcH2 accepts 
ubiquitin from E1 ubiquitin-activating enzyme and catalyzes lysine-11- and 
lysine-48-linked poly-ubiquitination (191). UbcH13, in contrast, catalyzes the 
synthesis of the non-canonical lysine-63-linked poly-ubiquitin chains which 
typically does not result in the degradation of the protein by the UPS 
(192,193).  HEK293T cells were transiently transfected with TRIM11 and 
UbcH2 or UbcH13. At 24 hour post-transfection, 10µM MG132 was added to 
the cells for 16 hours. Cells were harvested and cell lysates were subjected to 
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immuno-precipitation with anti-FLAG antibody. As illustrated in Fig 3.12, 
TRIM11 was found to interact with both E2 ubiquitin-conjugating enzymes 
that were capable of catalyzing the two main forms of poly-ubiquitination 
(namely lysine-48- and lysine-63-linkages). This may further support the 
notion that TRIM11 can interact with E2 ubiquitin-conjugating enzymes to 
potentially module the proteasome-mediated degradation of MOAP-1.    
 
 
Figure 3.12 TRIM11 interacts with E2 ubiquitin-conjugating enzymes, UbcH2 
and UbcH13. HEK293T cells were transiently transfected with MYC-FLAG-
TRIM11 and HA-UbcH2 or HA-UbcH13 for 24 hours. 10µM MG132 was then 
added to the cells for 16 hours. Cells were then harvested and cell lysates were 
immuno-precipitated with anti-FLAG. Cell lysates and immuno-precipitates were 
separated by SDS-PAGE and analyzed with western blotting. HSP60 was used as a 
loading control. 
 
3.2.7 TRIM11 catalyzes the poly-ubiquitination of MOAP-1 in vitro 
Since TRIM11 was shown to interact with and degrade MOAP-1, we 
next asked if direct E3 ubiquitin ligase activity of TRIM11 on MOAP-1 can be 
detected. To do so, we performed in vitro ubiquitination assay. In addition, 
GST-TRIM11 RING finger domain mutants (C16,19A and C31A,H33A) were 
used to validate if the RING finger domain of TRIM11 is required for the 
poly-ubiquitination of MOAP-1. In brief, FLAG-MOAP-1 and GST-TRIM11 
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[wild type (WT), C16,19A or C31A,H33A mutants] purified from bacteria 
were incubated with recombinant E1 enzyme, recombinant E2 ubiquitin-
conjugating enzyme (UbcH5C) and ubiquitin. UbcH5C was used as it is 
commonly used for in vitro ubiquitination reactions and is one the most active 
class of E2 ubiquitin-conjugating enzymes in cell extracts (194). Similar to 
UbcH2, UbcH5C was reported to accept ubiquitin from the E1 ubiquitin-
activating enzyme and catalyzes lysine-11- and lysine-48-linked poly-
ubiquitination (195). After the incubation, FLAG-MOAP-1 was solubilized 
and analyzed by western blotting using anti-ubiquitin antibody to detect 
ubiquitinated FLAG-MOAP-1 (Fig 3.13A). In a similar manner, for Fig 3.13B, 
reaction samples were boiled in 1% SDS to stop the reaction and then diluted 
ten times in 0.5% TNTE. The reaction samples were precipitated with anti-
FLAG antibody and analyzed by western blotting using anti-ubiquitin 
antibody to detect ubiquitin-conjugated FLAG-MOAP-1.     
As illustrated in Fig 3.13, a clear accumulation of poly-ubiquitinated 
MOAP-1 products was observed in the reaction mixture containing GST-
TRIM11, FLAG-MOAP-1, E1 enzyme, UbcH5C and ubiquitin (lane 4; Fig 
3.13A for total and Fig 3.13B for IP). While, in reaction mixtures where GST-
TRIM11 WT was substituted with the catalytically inactive mutants (C16,19A 
and C31A,H33A), the poly-ubiquitination of MOAP1 was abolished (lanes 5 
and 6 respectively). These results suggest that the in vitro poly-ubiquitination 
of FLAG-MOAP-1 is catalyzed by TRIM11 and E2 ubiquitin-conjugating 
enzyme, UbcH5C. In addition, the RING finger domain of TRIM11 is 
essential and required for the poly-ubiquitination of MOAP-1 by TRIM11.     





Figure 3.13 TRIM11 and UbcH5C catalyzed the in vitro poly-ubiquitination of 
MOAP-1 and the RING finger domain of TRIM11 is required for this poly-
ubiquitination of MOAP-1 by TRIM11 (A) FLAG-MOAP1 and GST-TRIM11 
[wild type (WT), C16,19A or C31A,H33A mutants] purified from bacteria were 
subjected to an in vitro ubiquitination assay. Samples were boiled in loading buffer to 
stop the reaction and loaded to SDS-PAGE directly for a western blotting assay. (B) 
Reaction samples were boiled in 1% SDS to stop the reaction, then diluted 10 times 
in 0.5% TNTE and precipitated with anti-FLAG antibody. Ubiquitin-conjugated 
MOAP-1 was then detected with anti-Ub antibody. The asterisk indicates that the data 
was provided by a collaborator from Xiamen University.   
 
3.2.8 Knock-down of endogenous TRIM11 in HEK293T does not alter the 
abundance of MOAP-1  
We have now shown that TRIM11 over-expression shortened the 
protein half-life of MOAP-1and TRIM11 possesses E3 ubiquitin ligase 
activity to ubiquitylate MOAP-1 in vitro. We next determined whether siRNA 
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knock-down of TRIM11 can increase the steady-state levels of endogenous 
MOAP-1 in HEK293T cells. Since we do not yet have a good antibody that 
can detect endogenous TRIM11 protein levels, real-time PCR was conducted 
to evaluate the knock-down efficiency of TRIM11. To do this, we transfected 
10 nM scrambled control siRNA and TRIM11 siRNA1-4 into HEK293T cells 
for 72 hours. Cells were then harvested for RNA isolation followed by reverse 
transcription to obtain the cDNA. The cDNA was then subjected to real-time 
PCR to quantify the mRNA levels of TRIM11. All four siRNAs of TRIM11 
reduced at least 50% of TRIM11 mRNA levels (Fig 3.14A).  
We then evaluated whether knock-down of endogenous TRIM11 can 
increase the steady-state levels of MOAP-1 in HEK293T cells. 10nM 
scrambled control siRNA and TRIM11 siRNA1-4 were transfected into 
HEK293T cells for 72 hours. As shown in Fig 3.14B, knockdown of 
endogenous TRIM11 did not increase the steady-state abundance of 
endogenous MOAP-1 in HEK293T cells. This may be due to low endogenous 
expression of TRIM11 in HEK293T cells resulting in negligible difference in 
protein abundance of MOAP-1 between the TRIM11 knock-down cells and 
control vector cells. In addition, similar results were obtained at 20 nM of 
TRIM11 siRNAs (data not shown). Due to concerns over off-target effects in 
which siRNAs may influence the expression of non-homologous or partially 
homologous gene targets (196,197), the knock-down analysis was not 
conducted at higher siRNAs concentrations.  





Figure 3.14 Knockdown of endogenous TRIM11 by siRNA did not alter 
MOAP-1 abundance in HEK293T cells. (A) Scrambled control siRNA and 
TRIM11 siRNA1-4 were transfected into HEK293T cells for 72 hours. Cells 
were then harvested for RNA isolation followed by reverse transcription to 
obtain the cDNA. The cDNA was then subjected to real-time PCR to quantify 
the mRNA expression of TRIM11. (B) Scrambled control siRNA and 
TRIM11 siRNA1-4 were transfected into HEK293T cells for 72 hours. Cells 
were then harvested and subjected to SDS-PAGE and analyzed by western 
blotting. Data shown are for immuno-blot analyses of MOAP-1 and loading 
control, HSP60.  
 
3.3 Discussion 
Characterized by a tripartite (also known as RBCC) motif that 
comprises a RING finger domain, a B-box and a coiled-coil domain at the N-
terminal region, the TRIM family of proteins have been shown to be involved 
in a number of critical intra-cellular processes including apoptosis, 
differentiation, cell differentiation and tumorigenesis (187). Several TRIM 
family members have been reported to demonstrate E3 ubiquitin ligase activity 
through their RING domain. In addition, some TRIM proteins have been 
reported to be involved in the regulation of the immune system but their exact 
mechanism of action remains to be elucidated (198,199). TRIM11 contains the 
RBCC domain and a C-terminal B30.2/SPRY domain (Fig. 3.1B). Recent 
studies have demonstrated the role of TRIM11 in innate immunity where it 
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was shown to be a negative regulator of type I interferons (IFNα/β) production 
(200).  In addition, TRIM11 has also been demonstrated to act in a RING 
domain-dependent manner to reduce the levels of TRIM5α protein, an 
inhibitor of HIV infection (201). As for its role as a E3 ubiquitin ligase, the 
following substrates have been identified: Humanin, a 24-amino-acid neuro-
protective peptide; activator-recruited co-factor 105-kDa component 
(ARC105), a component of the ARC complex that mediates chromatin-
directed transcription factors; and Pax6, a member of the paired-box homeo-
domain transcription factors; and PHOX2B, a paired-box homeo-domain 
transcription factor (202-205).  
Since it has been reported that higher levels of MOAP-1 in cancers 
cells are sufficient to enhance their sensitivity to chemotherapeutic drugs, 
targeting the E3 ubiquitin ligases of MOAP-1 to inhibit ubiquitin-mediated 
degradation and up-regulate MOAP-1 protein levels holds considerable 
therapeutic potential. Recent studies have also demonstrated that TRIM11 
functions as a RING E3 ubiquitin ligase degrading Humanin, ARC105, Pax6 
and PHOX2B (202-205). In this study, we demonstrated an important role for 
TRIM11, a member of the TRIM family of RING finger proteins, in regulating 
the ubiquitination and proteasome-mediated degradation of MOAP-1 protein.  
Unlike TRIM39, a close homologue of TRIM11, which has been 
reported to stabilize MOAP-1, TRIM11 interacts with and degrades MOAP-1 
through the ubiquitin proteasome system (Figs 3.2, 3.3, 3.6 and 3.7). 
Furthermore, mutation of conserved cysteine and histidine residues at 16, 19, 
31 and 33 in the RING finger domain of TRIM11 abrogated its ability to 
degrade MOAP-1 (Fig 3.11), suggesting that the RING finger domain of 
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TRIM11 is required for regulating the protein stability of MOAP-1. In 
addition, using in vitro ubiquitination assay, we showed direct poly-
ubiquitinating activity of TRIM11 on MOAP-1 (Fig 3.13).  
However, knock-down of endogenous TRIM11 in HEK293T cells by 
siRNAs did not increase the steady-state abundance of endogenous MOAP-1 
(Fig 3.14). This may be due to low endogenous expression of TRIM11 in 
HEK293T cells resulting in negligible difference in MOAP-1 abundance 
between the TRIM11-knockdown and vector control cells. Hence, more cell-
lines will need to be screened in the future to identify the cell-lines with higher 
endogenous levels of TRIM11. 
Collectively, this study suggests that TRIM11 may function as a 
putative E3 ubiquitin ligase of MOAP-1. To date, the APC/C
Cdh1
 has also been 
suggested to function as a MOAP-1 E3 ubiquitin ligase (104). However, it is 
likely that both proteins function as E3 ubiquitin ligases of MOAP-1 under 
different context (i.e. cell type, cell condition). It is also possible that TRIM11 
and APC/C
Cdh1











Evaluation of phosphorylation as a regulatory 
























Characterization study conducted by our laboratory has revealed that 
MOAP-1 is a short lived protein with a half-life of approximately 25 mins and 
it is constitutively degraded by the ubiquitin proteasome system (UPS) under 
non-apoptotic condition (67). On contrary, MOAP-1 is rapidly up-regulated by 
multiple apoptotic stimuli including endoplasmic reticulum (ER) stress 
inducer Thapsigargin (THA), DNA-damaging agents Etoposide (ETOP), 
serum withdrawal and death receptor TNF-related apoptosis-inducing ligand 
(TRAIL) (67). Similarly, the responsiveness of MOAP-1 up-regulation 
induced by different apoptotic stimuli differs in different cell-lines. For 
instance, the up-regulation of MOAP-1 by TRAIL and THA is most robust in 
HCT116, a colorectal cancer cell-line while the elevation of MOAP-1 by 
ETOP is best observed in HEK293T cell-line (67). Notably, pre-treatment of 
ETOP followed by proteasome inhibition by MG132 reduced the 
accumulation of ubiquitinated forms of MOAP-1 suggesting that the effect of 
apoptotic stimuli on stabilizing MOAP-1 is likely to be mediated through the 
inhibition of its poly-ubiquitination process (67). Although it was shown that 
post-translational instead of transcriptional or translational mechanisms plays 
a significant role in mediating the stabilization of MOAP-1 under apoptotic 
condition (67), the link between apoptotic stimuli and inhibition of MOAP-1 
poly-ubiquitination is still unknown.   
Phosphorylation is a widely used regulatory mechanism in biological 
systems to control cellular homeostasis. As a transient and reversible post-
translational modification, phosphorylation functions as a form of spatial and 
temporal regulation on macromolecules including the Bcl-2 family of proteins 
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such as Bim. Bim is one of the BH3-only pro-apoptotic proteins that activates 
Bax/Bak directly and inhibits anti-apoptotic proteins such as Bcl-2, Bcl-xL 
and Mcl-1, thereby releasing Bax/Bak to trigger the mitochondrial-mediated 
apoptotic pathway. Bim was found to undergo both post-translational 
modifications of ubiquitination and phosphorylation. Interestingly, 
phosphorylation of Bim at serine 65 by ERK was required for its association 
and degradation by its E3 ubiquitin ligase, TRIM2 (102). Since MOAP-1 has 
been shown to be regulated by the ubiquitin proteasome system, we 
hypothesized if MOAP-1 undergoes a similar regulation to Bim whereby 
phosphorylation of it may be required for its degradation via the UPS. While 
phosphorylation may modulate many aspects of a protein such as its intrinsic 
functional activity, folding and conformation, oligomerization state, sub-
cellular localization, protein-protein interaction, the scope of my thesis will 
look specifically at the potential role of phosphorylation in regulating the 
















4.2.1 In vitro phosphorylation assay of GST-MOAP-1  
In an attempt to determine the phosphorylation status of MOAP-1, a 
collaboration was set up with Jeffery Yong (Institute of Molecular and Cell 
Biology, Biopolis, Singapore) to conduct in vitro kinase assay using [γ-32P] 
ATP. Recombinant GST-MOAP-1 was expressed in bacterial strain BL21 
(DE3) and purified using glutathione sepharaose beads. The brain and liver 
from mouse were chosen as crude sources of protein kinase(s) to 
phosphorylate GST-MOAP-1 in the in vitro kinase assay. The brain has 
always been an organ of interest for the study of MOAP-1. MOAP-1 protein is 
found to be highly enriched in the brain whereas in other tissues, MOAP-1 
exists in very low abundance, presumably due to its constitutive regulation by 
the UPS. In addition, unpublished data from our laboratory suggest that 
MOAP-1 play an important role in Jo-2 mediated apoptosis in the liver. Hence, 
we were keen to evaluate if these organs possess potential kinases that are 
capable of phosphorylating recombinant GST-MOAP-1 in the in vitro kinase 
reaction. Brain and liver were harvested and purified using ion exchange 
chromatography (IEX). Briefly, IEX separates proteins based on their net 
surface charge through electrostatic interactions that occur between proteins 
and the charged column. “Salting out”, using increasing concentrations of salt 
solution (NaCl used in our case) is then used to release the proteins bound to 
the column. The column having higher attraction for the charged salts rather 
than the charged proteins, will release the protein in favour of binding to the 
salts instead. Correspondingly, proteins with weaker ionic interactions will 
elute first at lower salt concentration while higher salt concentrations will be 
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required to release proteins with stronger ionic interactions to the column. The 
purified elutes were then collected at 0.25M, 0.5M, 0.75M and 1M of NaCl. 
For the in vitro kinase reaction, GST-MOAP-1 was incubated with 10µM [γ-
32
P] ATP and the respective purified elutes for 30min at 30
o
C. Myelin basic 
protein (MBP) is a substrate for phosphorylation by several different protein 
kinases and was used as a positive control for the in vitro kinase assay.  
 
Figure 4.1 Autoradiography showed a band corresponding to the molecular 
weight of GST-MOAP-1 in the 0.5M brain elute reaction. A. Coomassie staining 
of the gel after SDS-PAGE electrophoresis. Bands corresponding to GST-MOAP-1 
and myelin basic protein (MBP) were observed (indicated with arrows). B. 
Autoradiography of the membrane showed a potential band corresponding to the 
molecular weight of GST-MOAP-1 (lane 5). For in vitro phosphorylation reaction, 
recombinant GST-MOAP-1 was incubated with 10 µM [γ-32P] ATP and the 
respective purified elutes for 30 min at 30 
o
C. The reactions were stopped by boiling 
in 2x SDS-PAGE sample buffer. Samples were separated on SDS-PAGE, stained 
with Coomassie blue and transferred to polyvinylidene difluoride membrane (PVDF) 
for autoradiography. 
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Based on the autoradiography obtained, the in vitro kinase reaction 
from 0.5M brain elute showed a band corresponding to the molecular weight 
of GST-MOAP-1 (Fig 4.1B, lane 5), suggesting that recombinant GST-
MOAP-1 may be phosphorylated by unknown protein kinase(s) present in the 
0.5M brain elute. While the band corresponding to molecular weight of myelin 
basic protein (MBP) gave a strong signal in the presence of brain lysate, 
suggesting that the in vitro kinase reaction worked as expected and MBP was 
phosphorylated by unknown protein kinase(s) found in the brain lysate during 
the in vitro kinase reaction (lane 13). However, it was observed that no band 
corresponding to the molecular weight of MBP was detected in the liver 
sample (lane 14). This could imply that there is low abundance of active 
protein kinases present in the liver lysate or the conditions for the harvest and 
purification of the liver organ were not yet optimized, leading to substantial 
protein degradation and the subsequent loss of enzymatic activity of the 
protein kinases.  
In an attempt to increase the signal for the putative phosphorylation 
signal of GST-MOAP-1 in the 0.5M brain lysate, we repeated the ion 
exchange column purification process for the 0.5M brain lysate elute. Similar 
to the first purification process, the elutions were collected at 0.25M, 0.5M 
and 0.75M of NaCl. The in vitro kinase assay was repeated with recombinant 
GST-MOAP-1, doubled purified brain elutes and 10µM [γ-32P] ATP for 
30min at 30
o









Figure 4.2 Autoradiography showed a band corresponding to the molecular 
weight of GST-MOAP-1 in the purified 0.5M brain elute reaction. For in vitro 
phosphorylation reaction, recombinant GST-MOAP-1 was incubated with 10 µM [γ-
32
P] ATP and the respective purified elutes for 30 min at 30 
o
C. The reactions were 
stopped by boiling in 2x SDS-PAGE sample buffer. Samples were separated on SDS-
PAGE, stained with GelCode Blue and transferred to PVDF membrane for 
autoradiography. 
 
Indeed, with a repeat of ion exchange column purification, a stronger 
signal corresponding to the molecular weight of GST-MOAP-1 was observed 
in the same elution concentration of 0.5M NaCl (Fig 4.2, lane 7). In addition, a 
strong signal corresponding to the molecular weight of MBP was observed 
(lane 10), suggesting that the in vitro kinase assay worked as expected. While 
the in vitro kinase assay using [γ-32P] ATP gave preliminary evidence 
suggesting that recombinant MOAP-1 can be phosphorylated by protein 
kinases present in the mouse brain, we were unable to confirm that the band 
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corresponding to the molecular weight of GST-MOAP-1 is indeed GST-
MOAP-1. More work would need to be conducted to confirm whether the 
putative phosphorylated band is MOAP-1 and to identify and characterize the 
kinase(s) present in the brain that phosphorylate recombinant GST-MOAP-1.   
In an attempt to detect phosphorylated forms of endogenous MOAP-1, 
we explored the possibility if the supplementation of PhosSTOP phosphatase 
inhibitor cocktail tablet (Roche) in the lysis buffer will allow a visual 
differentiation from the non-phosphorylation species of MOAP-1 and the 
detection of phosphorylated forms of MOAP-1 in western blotting. To address 
this, we harvested HEK293T cells treated with proteasome inhibitor, MG132 
and apoptotic stimuli known to up-regulate MOAP-1, Etoposide (ETOP). 
Protein samples were lyzed in lysis buffer supplemented with and without 
PhosSTOP phosphatase inhibitor cocktail tablet (Roche). SIRT1, a NAD
+
-
dependent deacetylase was reported to be a phospho-protein (206) and hence 
was immuno-blotted as a positive control.  
As expected, proteasomal inhibition by MG132 and DNA-damaging 
apoptotic stimuli, ETOP up-regulated protein levels of endogenous MOAP-1 
in HEK293T cells (Fig 4.3A). However, no noticeable difference in protein 
levels or migration species was observed. In contrast, the immuno-blot for 
SIRT1 showed a robust up-regulation of its protein levels in the presence of 
the PhosSTOP phosphatase inhibitor (Fig 4.3B). The data obtained from this 
experiment was not able to aid the detection of phosphorylated species of 
endogenous MOAP-1. It may suggest that that phosphorylation mechanism 
does not play a direct role in regulating the protein stability of endogenous 
MOAP-1 in HEK293T cells. However, it is premature to conclude that 
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MOAP-1 is not a phospho-protein. SIRT2, another member in the Sirtuins 
family of proteins, was also reported to be regulated by phosphorylation (207). 
However, similar to MOAP-1, no noticeable difference in its protein levels 
was observed in the presence or absence of PhosSTOP phosphatase inhibitor 




Figure 4.3 Supplementation of PhosSTOP phosphatase inhibitor cocktail tablet 
in the lysis buffer did not regulate the protein stability of MOAP-1. HEK293T 
cells were treated with proteasomal inhibitor, 10 μM MG132 and apoptotic stimuli, 
100 μM ETOP for 16 hours). The cells were harvested and subjected to SDS-PAGE 
and western blotting. HSP60 was used as an internal control to demonstrate that equal 
amount of proteins was loaded in each lane. 
 
4.2.2 Identification and mapping of phosphorylation sites on GST-
MOAP-1 
In an attempt to identify and map phosphorylation sites on recombinant 
GST-MOAP-1 by mass spectrometry analysis, we set up a collaboration with 
Li Rong from Experimental Therapeutics Centre, Biopolis, Singapore. In vitro 
phosphorylation of recombinant GST-MOAP-1 was carried out with the 
incubation of GST-MOAP-1, brain lysate and ATP in a kinase buffer at 30
o
C 
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for 30min. Reactions were stopped by boiling the samples in 2x SDS-PAGE 
sample buffer.  Protein samples were subjected to SDS-PAGE and the gels 
were subsequently submitted to the collaborator for mass spectrometry 
analysis.  
Three phosphorylation sites were identified in MOAP-1 from these 
samples. All three serine sites namely S27, S29 and S31 were found in one 
peptide (KALLIAGISQSCSVAEIEEALQAGLAPLGEYR). It is noteworthy 
however that these three serines are conserved only in chimpanzee human and 
monkey but not in mouse and rat (Fig 4.4). Though not identified by the mass 
spectrometry, another residue of interest in the MOAP-1 protein sequence is 
the conserved ERK phosphorylation motif (S/T)P, S173. (S/T)P motif has 
been reported to be potential sites of ERK phosphorylation (208). For this 
ERK conserved motif, it is only conserved in chimpanzee and human. 
Interestingly, just four amino acids away, we observed a serine that is 




Figure 4.4 Identification of five potential phosphorylation serine residues. 
Multiple protein sequence alignment was carried using ClustalW2 algorithm.  
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To evaluate the potential significance of these phosphorylation sites on 
the protein stability of MOAP-1, we conducted site-directed mutagenesis to 
generate a series of mutants of human MOAP-1 in which each of the five 
selected serines was substituted with either alanine or aspartate (Fig 4.5). The 
alanine substitution prevents phosphorylation at that residue and can mimic 
constitutively de-phosphorylated serine while the aspartate substitution can 




Figure 4.5 MOAP-1 mutants with point mutations at serine residues 27, 29, 31, 
169 and 173. Each mutant is listed and differences from the WT sequence are 
indicated in bold.  
 
Next, we tested the expression of these MOAP-1 mutants. HEK293T 
cells were used due to its high transfection efficiency. HA-MOAP-1 WT and 
the respective mutants were transfected in HEK293T cells and harvested after 
48 hours. Western blot analysis using HA antibody showed that mutants 
MOAP-1-3D and MOAP-1-5D have elevated protein expression compared to 
MOAP-1-WT or the other mutants (Fig 4.6) suggesting that constitutive 
phosphorylation at serine residues 27, 29 and 31 may be involved in mediating 
the protein stability of MOAP-1.  
 





Figure 4.6 Expression of MOAP-1 mutants in HEK293T cells. HEK293T cells 
were transfected with wild type (WT) and the respective MOAP-1 mutants for 48 
hours. Protein samples were harvested, separated on SDS-PAGE gel and analyzed 
with western blotting. HSP60 was used as an internal control to demonstrate that 
equal amount of proteins was loaded in each lane. 
 
4.2.3 Characterization of potential phosphorylation sites identified by 
mass spectrometry analysis 
Since it was observed that the MOAP-1-3D mutant has higher protein 
expression than the other mutants, we hypothesized that phosphorylation at the 
serine residues 27, 29 and 31 may stabilize MOAP-1 and consequently result 
in the higher abundance of protein levels observed. This led us to investigate 
the half-life of the MOAP-1-3D mutant using cycloheximide (CHX) chase 
assay. MOAP-1-WT, MOAP-1-3D and MOAP-1-2D mutants were transiently 
transfected in HEK293T cells. CHX, which inhibits de novo protein synthesis, 
was added to the cells at 24 hours post-transfection. Protein samples were 
harvested after 5 hours of CHX treatment.  
As shown in Fig 4.7, MOAP-1-3D mutant was indeed found to be 
more stable as compared to MOAP-1-WT (lanes 4 and 5), suggesting that 
phosphorylation at these serine residues 27, 29 and 31 may aid in stabilizing 
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MOAP-1, thereby extending its half-life. Notably, the expression of MOAP-1-
2D was very weak in this experiment and hence we were not able to conclude 
if the stability of MOAP-1-2D mutants were affected by constitutive 
phosphorylation at serine residues 169 and 173 (lane 3). For the CHX chase 
assay, Mcl-1, a short half-life Bcl-2 family protein, was used as a positive 
control to ensure that CHX blocked new protein synthesis in these cells while 




Figure 4.7 Mutation of serine (S) to aspartate (D) at residues 27, 29 and 31 
stabilized MOAP-1. HEK293T cells were transfected with HA-MOAP-1-WT, HA-
MOAP-1-3D and HA-MOAP-1-2D for 24 hours. 100 µg/ml cycloheximide (CHX) 
was added to the cells for 5 hours. Protein samples were harvested, separated on 
SDS-PAGE gel and analyzed with western blotting. Mcl-1 was used as a positive 
control to demonstrate that the CHX chase assay worked as expected.  HSP60 was 
used as an internal control to demonstrate that equal amount of proteins was loaded in 
each lane. 
 
The up-regulation of MOAP-1 by apoptotic stimuli has been well 
documented (67). Next, we investigated whether phosphorylation at serine 
residues 27, 29, 31, 169 and 173 are required for MOAP-1 up-regulation by 
apoptotic stimulus, ETOP. Alanine mutants MOAP-1-2A, MOAP-1-3A and 
MOAP-1-5A were transiently transfected into HEK293T cells along with a 
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vector control. ETOP was added to the cells at 24 hours post-transfection and 
were treated for 16 hours. The non-phosphorylatable mutants (MOAP-1-3A, 
MOAP-1-2A and MOAP-1-5A) were robustly up-regulated by ETOP, 
suggesting that phosphorylation at these residues may not play a significant 
role in mediating MOAP-1 stabilization by ETOP (Fig 4.8). Notably, MOAP-
1 has a total of 11 serine, 13 threonine and 6 tyrosine residues, all of which (in 
addition to the five serine residues examined) are potential phosphorylation 
sites that may be directly involved in the molecular regulation of MOAP-1 
under apoptotic treatment by ETOP. 
 
 
Figure 4.8 Up-regulation of the non-phosphorylatable alanine mutants by 
apoptotic stimulus, ETOP. HEK293T cells were transfected with HA-MOAP-1-3A, 
HA-MOAP-1-2A and HA-MOAP-1-5A for 24 hours. 100 µM Etoposide (ETOP) was 
treated to the cells for 16 hours. Protein samples were harvested, separated on SDS-
PAGE gel and analyzed with western blotting. HSP60 was used as an internal control 
to demonstrate that equal amount of proteins was loaded in each lane. 
 
4.2.4 Inhibition of MAPK and PI3K signaling cascades by chemical-based 
kinase inhibitors 
As mentioned, protein levels of endogenous MOAP-1 is elevated by 
multiple apoptotic stimuli including TRAIL, THA, ETOP, ultra-violet 
irradiation and serum withdrawal in multiple mammalian cell-lines such as 
293T, HCT116, SY5Y, HepG2, H1299 and HeLa cells (67). Notably, STS is 
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the only apoptotic stimulus tested that is unable to up-regulate endogenous 
protein levels of MOAP1 (67). Interestingly, STS is recognized as a wide-
spectrum ATP-competitive kinase inhibitor that binds to and inhibit many 
protein kinases with high affinity (209,210). 
 
4.2.4.1 Inhibition of MAPK signaling cascade 
It has been reported that the regulation and commitment of apoptosis 
involve kinase signaling pathways including, but not limited to, the mitogen-
activated protein kinase (MAPK) and the phosphatidylinositol 3-kinase (PI3K) 
pathways (211-213). The MAPK is a family of serine/threonine kinases that 
mediate intracellular signal transduction in response to various stimuli  (214). 
To date, major MAPKs include the extracellular signal-regulated kinases 
(ERK1/2), stress-activated protein kinases [c-Jun NH2-terminal kinases (JNK)] 
and p38 mitogen-activated protein kinases. Similarly, the PI3K pathway 
responds to a variety of extra- and intra-cellular signals that regulate many 
cellular processes such as apoptosis and cellular proliferation (116).   
We hypothesized that the up-regulation of endogenous MOAP-1 by 
multiple apoptotic stimuli may involve and depend on the MAPK and PI3K 
signaling pathways. To address this, we blocked the MAPK and PI3K 
signaling pathways using established chemical-based kinase inhibitors and 
evaluate if the up-regulation of MOAP-1 by apoptotic stimulus is affected. 
ETOP is one of the apoptotic stimuli that results in a robust up-regulation of 
endogenous MOAP-1 in HEK293T cells. Hence, ETOP and HEK293T cells 
were chosen as the apoptotic stimulus and cell-line to be used in the kinase 
inhibitors experiments. HEK293T cells were subjected to an hour of pre-
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treatment with the selected kinase inhibitors in the presence and absence of 
ETOP for 16 hours. Endogenous protein level of MOAP-1 was probed to 
evaluate if the up-regulation by apoptotic stimulus was blocked and HSP60 
was used as a loading control. It is noteworthy that the concentration of the 
kinase inhibitors used was based on concentrations that are widely used and 
accepted in the literature for inhibition of the respective kinases. In addition, 
before each harvest, cells were monitored in terms of their morphology and 
attachment to the petri dishes to ensure that the kinase inhibitors were not 
causing notable cyto-toxicity. Due to limitations in resources of the antibodies, 
positive controls such as immuno-blot of the targeted kinase and its 
downstream kinases were not conducted as a way for confirming the fidelity 
of the inhibitors used. However, validation of the results with over-expression 
of the specific kinase(s) will be conducted once preliminary data have shown 
sufficient evidence that the kinase(s) is/are involved in the molecular 
regulation of MOAP-1.  
SB203580 and DJNK1 are potent inhibitors of the p38 and JNK 
kinases respectively while PD98059 and U0126 are potent inhibitors of 
MEK1/2 kinase. SB203580 inhibits the catalytic activity of p38 by 
competitive binding in the ATP pocket (215) while DJNK1 is a JNK peptide 
inhibitor that inhibits the interaction between JNK and its substrate (216). At 
the concentrations tested, inhibition of p38 or JNK did not suppress the up-
regulation of endogenous MOAP-1 by ETOP (Fig 4.9 A&B). Although 
PD98059 and U0126 inactivate MEK1/2 through different mechanisms 
[PD98059 inhibits MEK1/2 by competitive binding to MEK1/2 thereby 
preventing the activation of MEK1/2 by its up-stream kinase, Raf (217) while 
 Chapter 4 
97 
 
U0126 directly inhibits MEK1/2 by acting on its catalytic properties (218)], 
both inhibitors showed significant effect in blocking the up-regulation of 
endogenous MOAP-1 by ETOP but did not affect basal levels of MOAP-1 
(Fig 4.9 C&D). These results suggest that the MEK1/2 (but not p38 or JNK 
kinases) and/or its downstream targets may be involved in mediating the 
elevation of endogenous protein level of MOAP-1 under apoptotic condition 












Figure 4.9 Chemical-based inhibition of p38, JNK and MEK signaling cascades. 
HEK293T cells were pre-treated with the respective kinase inhibitors at the indicated 
concentrations for 1 hour before being subjected to 100 µM ETOP treatment for 16 
hours. The cells were harvested and proteins were resolved by SDS-PAGE and 
analyzed with western blotting. HSP60 was used as an internal control to demonstrate 
that equal amount of proteins was loaded in each lane. (A) Inhibition of p38 by 
SB203580 did not block the elevation of MOAP-1 protein level by apoptotic stimulus, 
ETOP. (B) Inhibition of JNK by DNK1 did not suppress the up-regulation of 
endogenous MOAP-1 by ETOP. (C & D) Inhibition of MEK1/2 by PD98059 and 
U0126 respectively blocked the up-regulation of MOAP-1 by apoptotic stimulus, 
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4.2.4.2 Inhibition of PI3K signaling cascade 
Wortmannin and LY294002 are potent and commonly used inhibitors 
of PI3Ks. Wortmannin is a potent pan-specific inhibitor that occupies the 
ATP-binding site of p110 by forming a covalent bond between C20 of the 
Wortmannin furan ring and K802 of p100 of PI3K (219). However, 
Wortmannin has a half-life of only a few minutes in serum due to its highly 
reactive C20 position (220). LY294002, a reversible synthetic compound, 
makes a key hydrogen bond between the morpholino oxygen in the compound 
and the backbone amide of V882 of p110, mimicking the interaction made by 
adenine of ATP (221,222). PI3K inhibition by both Wortmannin and 
LY294002 showed significant effect in blocking the up-regulation of 
endogenous protein level of MOAP-1 by ETOP but did not affect basal levels 
of MOAP-1 (Fig 4.10 A&B) suggesting that the PI3K signaling pathway may 
potentially be also involved in mediating the molecular regulation of MOAP-1 
under apoptotic condition.  
 
 




Figure 4.10 Inhibition of PI3K signaling cascade by Wortmannin (A) and 
LY294002 (B) suppressed the up-regulation of endogenous protein level of 
MOAP-1 by apoptotic stimulus, ETOP. HEK293T cells were pre-treated with 
Wortmannin and LY294002 at the indicated concentrations for 1 hour before being 
subjected to 100 µM ETOP treatment for 16 hours. The cells were harvested and 
proteins were resolved by SDS-PAGE and analyzed with western blotting. HSP60 
was used as an internal control to demonstrate that equal amount of proteins was 
loaded in each lane.  
 
mTORC1 is a serine-threonine kinase that is a member of the 
phosphatidylinositol 3-kinase-related kinase (PIKK) family of kinases. 
mTORC1 exists as a complex consisting of mTOR with raptor, LST8 and 
AKTS1. Rapamycin is a specific and potent inhibitor of mTORC1 which 
inhibits mTORC1 by dissociating raptor from the complex (223). Since the 
inhibition of PI3K signaling pathway showed significant suppression of the 
up-regulation of endogenous MOAP-1 by ETOP and mTORC1 is a key 
downstream target of the PI3K signaling pathway, we asked if inhibition of 
mTORC1 by Rapamycin will give similar result as that observed by 
Wortmannin and LY294002 (Fig 4.10). Indeed, inhibition of mTORC1 by 
Rapamycin showed significant suppression of endogenous MOAP-1 elevation 
by ETOP (Fig 4.11).  





Figure 4.11 Suppression of mTORC by Rapaymycin blocked endogenous 
MOAP-1 up-regulation by apoptotic stimulus, ETOP. HEK293T cells were pre-
treated with Rapamycin at the indicated concentrations for 1 hour before being 
subjected to 100µM ETOP treatment for 16 hours. The cells were harvested and 
proteins were resolved by SDS-PAGE and analyzed with western blotting. HSP60 
was used as an internal control to demonstrate that equal amount of proteins was 
loaded in each lane.  
 
Although Wortmannin and LY294002 are widely employed as PI3K 
inhibitors, it was reported by several studies that they both have significant 
limitations and hence are not ideal inhibitors for PI3Ks  (224). While 
Wortmannin is a reactive electrophilic and hence unstable compound, 
LY294002 is a weak inhibitor with only micro-molar potency. Furthermore, 
both compounds display significant off-target effects on other kinases (224-
229). PI-103 is a relatively new potent, cell-permeable, ATP-competitive 
inhibitor that targets both PI3K and mTORC1 (230-233). As a multi-target 
inhibitor, PI-103 targets the catalytic domain of PI3K and mTORC1, 
delivering a powerful inhibition of the PI3K and mTORC1 pathways (228). It 
was reported that PI-103 exhibited advantages over Wortmannin and 
LY294002 in terms of its excellent potency, selectivity for PI3Ks and 
improved stability (224).  Thus, we asked if suppression of endogenous 
MOAP-1 up-regulation by ETOP will be observed under double inhibition of 
both PI3K and mTORC1 by PI-103. On contrary, inhibition of PI3K and 
mTORC1 by PI-103 did not suppress the elevation of endogenous MOAP-1 
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by apoptotic stimulus, ETOP (Fig 4.12). This contradicts the data obtained 




Figure 4.12 Dual inhibition of PI3K and mTORC did not suppress the up-
regulation of MOAP-1 by apoptotic stimulus, ETOP. HEK293T cells were pre-
treated with PI-103 at the indicated concentrations for 1 hour before being subjected 
to 100 µM ETOP treatment for 16 hours. The cells were harvested and proteins were 
resolved by SDS-PAGE and analyzed with western blotting. HSP60 was used as an 
internal control to demonstrate that equal amount of proteins was loaded in each lane.  
  
Taken together, it seems inconclusive whether the inhibition of PI3K is 
able to block the up-regulation of endogenous MOAP-1 under the treatment of 
ETOP. Although Rapamycin is recognized as an exquisitely specific inhibitor 
of mTORC1 (234), it may be premature to conclude that mTORC signaling 
pathway is directly involved in regulating the protein stability of MOAP-1 
under ETOP treatment. Remarkably, it was reported that Wortmannin can 
inhibit the chemotactic peptide-induced activation of MEK2, the predominant 
form in human neutrophils (235). In this scenario, it is conceivable that 
perhaps Wortmannin may inhibit the activation of MEK2 by ETOP treatment, 
thereby suppressing the up-regulation of MOAP-1 by ETOP. On contrary, 
there is no article found to date, that reports the inhibition on the MEK/MAPK 
signaling pathway by PI3K inhibitor, LY294002. Hence, we decided to focus 
our study on the MEK/MAPK signaling cascade, since inhibition of MEK1/2 
by both PD98059 and U0126 have consistently suppressed the elevation of 
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endogenous MOAP-1 by ETOP, suggesting that MEK and/or its downstream 
targets are likely to be involved in mediating the up-regulation of endogenous 
MOAP-1 under DNA-damaging apoptotic stimulus, ETOP in HEK293T cells.  
 
4.2.5 ETOP activates the ERK/MAPK signaling cascade 
It was reported that ERK is activated by DNA damaging signals such 
as ETOP which interferes with the function of DNA topoisomerase II leading 
to the breakage of double-strand DNA (236,237). We asked if such 
phenomenon will be observed in HEK293T cells under ETOP treatment. To 
address this, we treated 100µM ETOP to HEK293T cells for the indicated 
duration. As shown in Fig 4.13, ERK activation was rapidly observed under 
the treatment of ETOP.  
 
Figure 4.13 ETOP activates ERK in HEK293T cells. HEK293T cells were starved 
with serum-free DMEM for 16 hours overnight. Cells were then subjected to 100 µM 
ETOP treatment for the indicated duration. The cells were harvested and subjected to 
SDS-PAGE and western blotting. Total ERK was used as an internal control to 
demonstrate that equal amount of proteins was loaded in each lane. 
 
4.2.6 MEKΔ is involved in regulating the protein stability of MOAP-1 
Results obtained from the inhibition of MEK1/2 by PD98059 and 
U0126 suggest that molecular targets in the MAPK signaling cascade may be 
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involved in mediating the up-regulation of endogenous MOAP-1 under ETOP 
treatment. Hence, we asked if over-expression of constitutively active S218, 
222D MEK1 (referred to as MEK1Δ in this report) (238), a key regulatory 
kinase in the MAPK signaling cascade, will regulate the protein level of 
MOAP-1 under co-expression and single expression conditions. For the co-
expression experiment, HEK293T cells were transiently transfected with 
expression vectors encoding FLAG-MOAP-1 and HA-MEK1Δ. While for the 
single expression experiment, HEK293T cells were transiently transfected 
with HA-MEK1Δ along with a vector control and harvested after 48 hours. As 
illustrated in Fig 4.14, MEK1Δ resulted in a robust up-regulation of FLAG-
MOAP-1 (A) and endogenous MOAP-1 (B), suggesting the possible 
involvement of MEK1 in mediating the protein stability of MOAP-1. In 
addition, over-expression of MEK1Δ also induced the activation of ERK, a 




Figure 4.14 MEK1Δ up-regulates exogenous (A) and endogenous (B) protein 
level of MOAP-1 in HEK293T cells. (A) For co-expression experiment, HEK293T 
cells were transfected with HA-MEK1Δ and FLAG-MOAP-1 for 48 hours. (B) 
HEK293T cells were transfected with HA-MEK1Δ along with a vector control for 48 
hours.  The cells were harvested and subjected to SDS-PAGE and western blotting 
analysis. HSP60 (in A) and total ERK (in B) were used as internal control to 
demonstrate that equal amount of proteins was loaded in each lane.  
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4.2.7 MEKΔ interacts with MOAP-1 
Next, we asked if a physical interaction between MOAP-1 and 
MEK1Δ can be observed. To address this, HEK293T cells were transiently 
transfected with expression vectors encoding MYC-MOAP-1 and HA-
MEK1Δ for 48 hours. The cells were then harvested and equal amounts of 
total cell lysates were subjected to immuno-precipitation (IP) with either HA 
or MYC antibodies. As shown in Fig 4.15, MOAP-1 was found to interact 
with MEK1Δ under co-expression condition in HEK293T cells suggesting that 
MEK1Δ may play a direct role in mediating the protein stability of MOAP-1.  
 
 
Figure 4.15 MEK1Δ interacts with MOAP-1. HEK293T cells were transiently 
transfected with MYC-MOAP-1 and HA-MEK1Δ for 48 hours. The cells were 
harvested and equal amounts of total cell lysates were immuno-precipitated with anti-
HA (in A) and anti-MYC (in B). Immuno-precipitates were immuno-blotted with 
anti-MYC (in A) and anti-HA (in B). The cell lysates and immuno-precipitates were 
resolved by SDS-PAGE and analyzed by western blotting. 
 
4.2.8 MEKΔ stabilizes MOAP-1 by extending its half-life 
Next, we asked if MEK1Δ up-regulates MOAP-1 by influencing the 
protein stability of MOAP-1. Using the cycloheximide (CHX) chase assay, we 
investigated the effect of MEK1Δ on the half-life of exogenous and 
endogenous MOAP-1 in HEK293T cells. For the study on exogenous MOAP-
1, 100µg/ml CHX was added to HEK293T cells transiently over-expressing 
both FLAG-MOAP-1 and HA-MEK1Δ. Steady-state protein levels of FLAG-
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MOAP-1 were assessed at 1, 3 and 5 hours after CHX treatment. As for the 
study on endogenous MOAP-1, HEK293T cells were transfected with HA-
MEK1Δ along with a control vector. At 24 hours post-transfection, 100µg/ml 
CHX was added to the cells. Steady-state protein levels of endogenous 
MOAP-1 were monitored at 0.5, 1 and 2 hours after CHX treatment.  
As shown in Fig 4.16A, in the presence of MEK1Δ, FLAG-MOAP-1 
was up-regulated and stabilized even at 5 hours of CHX treatment, suggesting 
that MEK1Δ up-regulates exogenous MOAP-1 via stabilization of the MOAP-
1 protein. Mcl-1, a short half-life Bcl-2 family protein, was used as a positive 
control to ensure that CHX blocked new protein synthesis in these cells. 
Similar results on the protein turn-over of endogenous MOAP-1 were obtained 
from single over-expression of MEK1Δ. As demonstrated in Fig 4.16B, in the 
presence of MEK1Δ, endogenous MOAP-1 was stabilized. Taken together, the 
results suggest that MEK1Δ may have a direct role in modulating protein 
stability of MOAP-1 by extending its half-life of MOAP-1.  
Notably, even though the CHX chase assay is commonly used in 
assaying protein stability, there are limitations with this assay. CHX inhibits 
the de novo protein synthesis of all proteins in the cells treated. This would 
imply that apart from MOAP-1, all other proteins including positive or 
negative regulators of MOAP-1 with relatively short half-life will be rapidly 
degraded. For instance, degradation of MOAP-1 may be reduced if the E3 
ubiquitin ligase of MOAP-1 is also rapidly degraded due to the CHX treatment. 
Indeed, many E3 ubiquitin ligases including MDM2 have the ability to 
promote self-ubiquitination, resulting in their rapid degradation and short half-
lives (239). 






Figure 4.16 MEK1Δ stabilizes exogenous (A) and endogenous (B) MOAP-1 by 
extending its half-life. (A) HEK293T cells were transiently transfected with HA-
MEK1Δ and FLAG-MOAP-1. At 24 hours post-transfection, the cells were treated 
with 100 μg/ml cycloheximide (CHX) for the indicated duration. After treatment, the 
cells were harvested and subjected to SDS-PAGE and western blotting analysis. Mcl-
1 was used as a positive control to demonstrate that the CHX assay worked as 
expected. HSP60 was used as an internal control to demonstrate that equal amount of 
proteins was loaded in each lane. (B) HEK293T cells were transfected with HA 
MEK1Δ for 24 hours. The cells were treated with 100 μg/ml CHX for the indicated 
duration. After treatment, the cells were harvested and subjected to SDS-PAGE and 
western blotting analysis. HSP60 was used as an internal control to demonstrate that 
equal amount of proteins was loaded in each lane.  
 
Furthermore, it was observed that exogenous MOAP-1 is more stable 
than its endogenous form as the former requires up to 5 hours of CHX 
treatment for visible degradation (Fig 4.16). One possible explanation could be 
the difference in cellular localization between endogenous and exogenous 
MOAP-1. While endogenous MOAP-1 has been shown to be enriched in the 
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mitochondrial fraction (66), exogenous MOAP-1 was observed to be localized 
in the cytoplasm by confocal microscopy analysis (refer to Chapter 5 Fig 5.2). 
This may suggest that the degradation of MOAP-1 via the ubiquitin 
proteasome system may require MOAP-1 to be localized near or in the 
mitochondrial and hence may suggest the involvement of mitochondrial E3 
ubiquitin ligase(s) for the degradation of MOAP-1. 
4.2.9 Alanine mutations at serine residues 27, 29 and 31 abolished 
MEK1Δ-mediated stabilization of MOAP-1 
Previously, we showed that the mutation of serine to aspartate at 
residues 27, 29 and 31 resulted in the protein stability of MOAP-1 (Fig 4.7). 
Next, we asked if these serine residues are required for the stabilization of 
MOAP-1 by MEK1Δ. To do this, HEK293T cells were transiently transfected 
with HA-MOAP-1-WT or HA-MOAP-1 alanine mutant (HA-MOAP-1-3A) 
and HA-MEK1Δ for 48 hours. As shown in Fig 4.17, mutation of serine to 
alanine at residues 27, 29 and 31 abolished the up-regulation of MOAP-1 by 
MEK1Δ, suggesting that phosphorylation at these residues may be required 
for the up-regulation and stabilization of MOAP-1 by MEK1Δ.  
 
Figure 4.17 Mutation of serine (S) to alanine (A) abolished the stabilization of 
MOAP-1 by MEK1Δ. HEK293T cells were transiently transfected with HA-MEK1Δ, 
HA-MOAP-1-3A mutant and HA-MOAP-1-WT for 48 hours. Cells were harvested 
and subjected to SDS-PAGE and analyzed by western blotting. HSP60 was used as a 
loading control to demonstrate that equal amounts of cell lysates was loaded into each 
lane.  
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4.2.10 MEK1Δ enhances susceptibility of HCT116 cells to TRAIL-induced 
Bax-activation  
Knock-down analysis of MOAP-1 has provided evidence to support an 
effector role for MOAP-1 in facilitating Bax signaling in mitochondria (66). 
Furthermore, stable over-expression of MOAP-1 in mammalian cells resulted 
in sensitization of cells to apoptotic stimuli such as THA and TRAIL (67). 
Isolated mitochondria from these cells were also more sensitive to the 
cytochrome c releasing effect of recombinant Bax (67). Since MEK1Δ is able 
to stabilize MOAP-1, we asked whether it may have an effect on promoting 
Bax signaling similar to over-expression of MOAP-1. In agreement with this, 
we investigated the effect of over-expression of MEK1Δ on TRAIL-induced 
Bax-activation in HCT116 cells. To do this, HCT116 cells were transiently 
transfected with HA-MEK1Δ along with a control vector for 24 hours. The 
indicated concentration of TRAIL was then added to the cells for 5 hours. The 
cells were harvested and equal amounts of total cell lysates were immuno-
precipitated with conformation-specific anti-Bax antibody, N20 which 
recognizes an epitope in the N-terminal domain of Bax that is exposed only 
after Bax acquires a membrane-insertion competent conformation (240). 
As shown in Fig 4.18, TRAIL-induced Bax activation was observed at 
a lower concentration of TRAIL treatment in MEK1Δ-over-expressing 
HCT116 cells as compared vector control cells. In addition, cleaved caspase 7, 
a classical apoptotic marker, was also detected at lower concentration of 
TRAIL treatment in the MEK1Δ-over-expressing cells. Taken together, these 
observations suggested that elevated levels of MOAP-1 caused by the 
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stabilization effect of MEK1Δ could result in enhanced Bax-activation and 




Figure 4.18 MEK1Δ sensitizes HCT116 cells to TRAIL-induced Bax activation 
and apoptosis. HCT116 cells were transiently transfected with HA-MEK1Δ along 
with a control vector for 24 hours. The indicated concentration of TRAIL was added 
to the cells for 5 hours. Extracts were prepared in 2% CHAPS lysis buffer and equal 
amounts of total cell lysates were immuno-precipitated with the conformation 
specific anti-Bax antibody, N20 which detects the activated form of Bax. Cell lysates 




Phosphorylation is a major post-translational modification (PTM) 
mechanism that regulates the function of many Bcl-2 family proteins (69). 
Reversible phosphorylation and dephosphorylation cascades modulated by 
kinases and phosphatases are two of the main mechanisms that directly 
regulate the function and conformation of both pro-survival and pro-apoptotic 
members of the Bcl-2 protein family (69). It is widely believed that for some 
proteins, protein phosphorylation plays a critical role in mediating protein 
ubiquitylation and hence determines whether a protein is targeted for 
degradation by the UPS (241). Thus, the phosphorylation status of a protein 
could either inhibit or promote protein ubiquitylation leading to either protein 
accumulation or degradation. 
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Data from the chemical-based kinase inhibition of the MAPK and 
PI3K signaling pathways prompted us to investigate the involvement of 
MAPK signaling pathway in mediating the protein stability of MOAP-1. 
Remarkably, MEK1Δ was found to interact with and stabilize MOAP-1 by 
extending its half-life (Fig 4.14 – 4.16). Furthermore, over-expression of 
MEK1Δ was shown to sensitize HCT116 cells to TRAIL-induced Bax 
activation and TRAIL-mediated apoptosis (Fig 4.17), suggesting that MEK1 
may possibly be a potential target to modulate the sensitivity of cancer cells to 
chemotherapeutics through the modulation of MOAP-1 protein stability.  
Interestingly, substitution of serine (S) to aspartate (D) at residues 27, 
29 and 31 stabilized MOAP-1 as demonstrated in the cycloheximide (CHX) 
chase assay (Fig 4.7) suggesting the potential involvement of direct 
phosphorylation at these sites in mediating the protein stability of MOAP-1. 
Furthermore, alanine substitution of serine residues at 27, 29 and 31 abolished 
the up-regulation of MOAP-1 by MEK1Δ (Fig 4.18), suggesting that 
phosphorylation at these sites may be required for the stabilization effect of 
MOAP-1 by MEK1Δ. Although in vivo interaction between MOAP-1 and 
MEK1Δ was detected under co-expression condition (Fig 4.15), it remains 
unclear whether MOAP-1 could be a direct substrate of MEK1Δ or its 
downstream targets. Furthermore, attempts to detect interaction between 
MEK1Δ and endogenous MOAP-1 were not successful (data not shown). 
More importantly, the substrate specificity of MEK1 (242,243) makes it 
unlikely that MEK1 itself functions as a MOAP-1 kinase. As such, it seems 
more conceivable that ERK1 and/or ERK2 may phosphorylate MOAP-1 
directly or through activation of other downstream kinases. To date, direct 
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phosphorylation of Bcl-2 family proteins by ERK or its downstream targets 
has been reported in many investigations. For instance, it was documented that 
ERK has the capacity to phosphorylate and inactivate anti-apoptotic activity of 
Bcl-2 and thus acts as regulator of the induction of apoptosis (244). Similarly, 
ERK1/2 can also directly phosphorylate and activate ribosomal s6 kinase, 
p90rsk which in turn phosphorylates and inactivates pro-apoptotic Bad in the 
mitochondria, resulting in cellular protection (245). 
Results showed in this study have demonstrated that constitutive 
phosphorylation of MOAP-1 at serines 27, 29 and 31 mediates the protein 
stability of MOAP-1 and are required for MEK1Δ-mediated stabilization of 
MOAP-1. It is plausible that activation of the MAPK signaling cascade by 
DNA damaging apoptotic stimulus, ETOP resulted in the phosphorylation of 
MOAP-1 which could have result in a change in protein conformation that 
subsequently deters the E3 ubiquitin ligase from recognizing and targeting 
MOAP-1 for degradation through the UPS. In addition, a second possibility is 
that activated ERK1/2 or its downstream targets may inactivate or cause the 
degradation of the E3 ubiquitin ligase of MOAP-1 thereby resulting in reduced 
ubiquitination of MOAP-1 and consequently its degradation by the UPS.  
Although the kinase of MOAP-1 has not yet been identified, this study 
provides further insight to enhance our understanding of the mechanisms that 
serve to regulate MOAP-1 and its role as a potential effector for MAPK-











Identification of Sirtuins as a novel interactors and 
























 Sirtuins belong to the class III protein deacetylases family, which are 
the only histone deacetylases (HDACs) that require NAD for their enzymatic 
activity (246). NAD is a vital co-factor for the electron transport chain and is 
also involved in many enzymatic reactions (247). Due to their characteristic 
NAD requirement for their enzymatic reaction, the activity of sirtuins has been 
directly associated with the metabolic state in the cell. In the last decade, 
sirtuins have emerged as a crucial family of enzymes in the regulation of 
eukaryotic metabolism. In mammalians, sirtuins control whole body metabolic 
homeostasis and are postulated as promising targets for multiple patho-
physiological states, including cancer, neuro-degeneration and cardiovascular 
disease (248,249). An emerging trend from these studies is that sirtuins may 
have critical roles in the regulation of apoptosis. Interestingly, some members 
of the sirtuin family have been shown to be localized in mitochondria. 
Ubiquitination is thus far the only PTM of MOAP-1 established and the 
involvement of deacetylases in the molecular regulation of MOAP-1 has not 
been reported previously. Hence, we asked if sirtuins may be involved in 











5.2.1 Subcellular co-localization profiles of MOAP-1 and SIRT1-5 
To evaluate the potential interaction between MOAP-1 and sirtuins, we 
conducted a preliminary evaluation on the subcellular co-localization between 
MOAP-1 and sirtuins. SIRT1-5 are included in this scope of study as SIRT1-5 
are localized either in the cytosol or in mitochondria in which MOAP-1 has 
been previously reported to be present under physiological conditions. SIRT6 
and SIRT7 are excluded due to their exclusive localization in the nucleus and 
nucleolus respectively. HeLa cells were transiently transfected with plasmids 
encoding GFP-MOAP-1 and FLAG-SIRT1-5 for 48 hours. Transfected cells 
were then analyzed by in-direct immuno-fluorescence analysis for GFP and 
FLAG –antibodies.   
Though endogenous MOAP-1 has been reported to be enriched in the 
mitochondria fraction (66), over-expressed GFP-MOAP-1 was observed to 
localize diffusely in the cytosol (Fig 5.1). As illustrated in Fig 5.1, SIRT1 is to 
be localized in both the nuclear and cytosol compartments. However, in our 
confocal microscopy analysis of FLAG-SIRT1, it was revealed that SIRT1 is 
mainly localized in the cytosol (Fig 5.1A). Notably, it was reported that SIRT1 
is localized in the nucleus of normal cells, but is predominantly localized in 
the cytosol of the cancer/transformed cells (250). Since HeLa, a human 
cervical cancer cell-line, was used in this confocal microscopy analysis, the 
finding in the report may aid in explaining why cytosolic SIRT1 was observed 
in our study. In agreement with the literature, our confocal microscopy 
analysis demonstrated that SIRT2 is primarily localized in the cytosol (Fig 
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5.1B). Similarly, for mitochondrial proteins SIRT3 and SIRT4, they are, as 
reported, primarily localized in the mitochondria, revealing the mitochondrial 
structure and network of the transfected cell (Fig 5.1C-D). On contrary, while 
SIRT5 is reported to be a mitochondrial protein (176), our confocal 
microscopy analysis did not illustrate such findings. Instead, both cytosol and 
nuclear localization of SIRT5 were observed (Fig 5.1E). Notably, it was 
reported by Pfister et al. that SIRT5 is generally localized to both the nucleus 
and cytosol while mitochondrial localization of SIRT5 is associated with 
apoptosis (251). 
An overlay of the confocal images for GFP-MOAP-1 and FLAG-
SIRT1-5 revealed that SIRT2 and SIRT5 showed strong co-localization with 
MOAP-1 (depicted by the shades of yellow in the overlay images as shown in 
Fig 5.1B and Fig 5.1E respectively). Zoomed-in images of strong co-
localization between MOAP-1 and SIRT2/5 are illustrated in Fig 5.2. Notably, 
it was difficult to identify cells which had the expression of both GFP-MOAP-
1 and SIRT proteins especially for SIRT1 and SIRT4. It may be due to weaker 
expression of the SIRT1/4 plasmids. In addition, it would be interesting to 
evaluate if over-expression of SIRT1/4 destabilizes MOAP-1 thereby resulting 
in MOAP-1 degradation and elimination from the cell.  
 





Figure 5.1 Subcellular co-localization of MOAP-1 and SIRT1-5 (depicted in 
panels A-E respectively) in HeLa cells. Immuno-fluorescent images from confocal 
microscopy analysis in HeLa cells transiently transfected with plasmids encoding 
GFP-MOAP-1 and FLAG-SIRT1-5. Transfected cells were then analyzed by 
immuno-fluorescence analysis for GFP and FLAG-antibody conjugated with the red 
Cy3 dye. 





Figure 5.2 Single cell confocal images of MOAP-1 and SIRT2/5 (depicted in 
panels A and B respectively. Immuno-fluorescent images from confocal microscopy 
analysis in HeLa cells transiently transfected with plasmids encoding GFP-MOAP-1 
and FLAG-SIRT1-5. Transfected cells were then analyzed by immuno-fluorescence 
analysis for GFP and FLAG-antibody conjugated with the red Cy3 dye. 
 
5.2.2 MOAP-1 interacts with SIRT2 and SIRT5  
Although confocal microscopy analysis provided preliminary evidence 
to support that MOAP-1, SIRT2 and SIRT5 are present in the same subcellular 
compartment, protein-protein interaction between MOAP-1 and SIRT1-5. To 
address this, co-immuno-precipitation was conducted to determine interaction 
between endogenous MOAP-1 and SIRT1-5 in HEK293T cells. HEK293T 
cells were used due to its high transfection efficiency. As illustrated in Fig 5.3, 
SIRT2 and SIRT5 interacted with endogenous MOAP-1 in HEK293T cells 
suggesting that SIRT2 and SIRT5 may be directly involved in mediating the 
protein abundance or function of MOAP-1. In the same context, MOAP-1 may 
also be directly involved in modulating the protein stability or activity of 
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SIRT2 and SIRT5. Additionally, MOAP-1 may serve as a binding protein 
which is required for SIRT2 and SIRT5 to function properly.   
 
Figure 5.3 Endogenous MOAP-1 interacts with exogenous SIRT2 and SIRT5. 
HEK293T cells were transiently transfected with FLAG-SIRT1-5 for 24 hours. Cells 
were harvested and cell lysates were immuno-precipitated with anti-MOAP-1 
antibody. Cell lysates and immuno-precipitates were subjected to SDS-PAGE and 
analyzed with western blotting.  
 
SIRT2 and SIRT 5 have previously been reported to be involved in the 
acetylation of metabolic enzymes in response to nutrient availability and hence 
have consequently emerged as integral components of the nutrient-sensing 
metabolic regulatory circuit (252). To determine whether the interaction 
between MOAP-1 and SIRT2/5 depends on nutrients availability, the protein-
protein interaction profile of MOAP-1 and SIRT2/5 were investigated under 
serum starvation. As illustrated in Fig 5.4, interaction between endogenous 
MOAP-1 and SIRT5 was abolished under serum starvation while the 
interaction between MOAP-1 and SIRT2 remained unchanged. This may 
suggest that the MOAP-1:SIRT5 interaction is regulated by nutrient 
availability. In addition, consistent with previously reported data, MOAP-1 is 
up-regulated upon serum starvation and serum starvation-mediated up-
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regulation of MOAP-1 is not affected by over-expression of SIRT2 and SIRT5 
(Fig 5.4).  
 
Figure 5.4 Serum starvation abolish the interaction between MOAP-1 and 
SIRT5. HEK293T cells were transiently transfected with FLAG-SIRT2 or FLAG-
SIRT5 for 24 hours. Cells were then starved with serum free medium and harvested 
after 24 hours. Cells were harvested and cell lysates were immuno-precipitated with 
anti-MOAP-1 antibody. Cell lysates and immuno-precipitates were subjected to SDS-
PAGE and analyzed with western blotting. HSP60 was used as a loading control to 
demonstrate that equal amounts of cell lysates was loaded into each lane. *denotes 
IGG bands.   
In addition, endogenous interaction between SIRT2 and MOAP-1 was 
investigated in HEK293T cells while the endogenous interaction between 
MOAP-1 and SIRT5 remains to be determined in future work. Cells over-
expressing SIRT2 were used as positive control to validate the specificity of 
the SIRT2 antibody. HEK293T cell lysates were immuno-precipitated with 
anti-MOAP-1 antibody and rabbit IgG antibody as negative control. Cell 
lysates and immuno-precipitates were subjected to SDS-PAGE and analyzed 
using western blotting. As demonstrated in Fig 5.5, endogenous interaction 
between MOAP-1 and SIRT2 was detected, suggesting that SIRT2 may 
indeed be a protein partner of MOAP-1.     





Figure 5.5 Endogenous interaction between MOAP-1 and SIRT2 was observed 
in HEK293T cells. HEK293T cell lysates were immuno-precipitated with anti-
MOAP-1 antibody and rabbit IGG antibody as negative control. Cell lysates and 
immuno-precipitates were subjected to SDS-PAGE and analyzed with western 
blotting. Cells over-expressing SIRT2 were used as positive control to validate the 
specificity of the SIRT2 antibody. 
 
5.2.3 SIRT5 suppresses ETOP-mediated up-regulation of MOAP-1  
It has been well validated in our laboratory that proteasome inhibition 
and apoptotic stimuli can up-regulate endogenous protein level of MOAP-1. 
Since SIRT2 and SIRT5 are deacetylases and acetylation has been reported to 
compete with ubiquitination for lysine residues and hence regulate protein 
stability (253), we investigated whether over-expression of SIRT2 or SIRT5 
affects the protein levels of MOAP-1 under DNA-damaging apoptotic 
stimulus, ETOP. Notably, over-expression of SIRT5, but not SIRT2, 
suppressed the up-regulation of MOAP-1 by ETOP (Fig 5.6) suggesting that 
SIRT5 may mediate the protein stability of MOAP-1 under DNA-damaging 
apoptotic stimuli. 





Figure 5.6 Over-expression of SIRT5 blocked MOAP-1 protein stabilization by 
ETOP. HEK293T cells were transiently transfected with FLAG-SIRT2 or FLAG-
SIRT5 for 24 hours. Cells were then treated with 10µM MG132 or 100µM ETOP for 
16 hours. Cells were harvested and protein samples were subjected to SDS-PAGE 
and analyzed with western blotting. HSP60 was used as a loading control to 
demonstrate that equal amounts of cell lysates was loaded into each lane.   
 
5.3 Discussion 
Sirtuins have emerged as a promising group of proteins which have 
been reported to play key roles in various cellular processes including, but not 
limited to, energy metabolism, apoptosis and cell proliferation. Since sirtuins 
use NAD
+
 as a co-factor, they have been intimately linked to metabolic status 
of cells (254). In the same way, sirtuins have emerged as integral components 
of the nutrient-sensing metabolic regulatory circuit, mediating nutrient 
availability and the regulation of various metabolic enzymes  (252).     
Sub-cellular localization and protein-protein interaction profiling are 
both classical approaches used to study novel functions of a protein. In 
particular, protein-protein interactions are intrinsic to virtually all cellular 
processes and confer a large degree of regulation in the cells. As a result, roles 
and significance of a protein in the cell could be deduced by identifying its 
interaction network and subsequently the consequences of the interactions 
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(255). In an attempt to draft a framework to set directions for future 
investigations on elucidating novel functions of MOAP-1, we explored the 
sub-cellular localization and protein-protein interaction profiles of MOAP-1 
and sirtuins in this study. 
Confocal microscopy analysis revealed that SIRT2 and SIRT5 strongly 
co-localized with MOAP-1 in HeLa cells (Fig 5.1B&E and Fig 5.2) leading us 
to investigate for physical interaction between these proteins. Using co-
immuno-precipitation assay, endogenous MOAP-1 was found to interact 
physically with exogenous SIRT2 and SIRT5 in HEK293T cells (Fig 5.3). 
Interestingly, serum starvation abolished the interaction between MOAP-1 and 
SIRT5 but not between MOAP-1 and SIRT2, suggesting that MOAP-1 may 
exist as a complex with SIRT2 under nutrient deprivation condition, mediating 
the regulation of various metabolic enzymes. Furthermore, endogenous 
interaction between MOAP-1 and SIRT2 was detected in HEK293T cells (Fig 
5.5) lending further support to the notion that MOAP-1 could be participating 
with SIRT2 in many cellular functions.  
Interestingly, SIRT5 selectively blocked ETOP-mediated up-regulation 
of MOAP-1 (Fig 5.6) but serum starvation-induced elevation of MOAP-1 was 
not affected by over-expression of SIRT5 (Fig. 5.4). This reinforces the notion 
that the underlying molecular steps and regulators involved in modulating the 
protein stability of MOAP-1 may be distinct for individual stimulus (67). In 
addition, studies have established that acetylation, similar to phosphorylation, 
can alter the protein conformation and hence manipulate whether a protein is 
recognized and targeted for degradation (256). Alternatively, acetylation may 
compete with ubiquitination for lysine residues and hence mediate the steady-
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state turnover of a protein (253). Since SIRT5 possess deacetylation activity, it 
is conceivable that acetylation of MOAP-1 may be required for its ETOP-
mediated up-regulation. Notably, it was reported that in addition to its function 
as a deacetylase, SIRT5 may also act as demalonylase and desuccinylase (153), 
giving rise possibility that MOAP-1 may be regulated by malonylation and 
succinylation too.  
In addition, it was also reported that SIRT5 may have an anti-apoptotic 
role as knockdown of SIRT5 resulted in the down-regulation of Bcl-xL and a 
marked reduction in cell viability and an increase in apoptotic cell number 
(257). This study may lend some support to our finding as MOAP-1 has been 
shown to be an effector of Bax-mediated apoptosis. Hence, the suppression of 
ETOP-mediated up-regulation of MOAP-1 by SIRT5 may further reinforce its 
reported anti-apoptotic function.   
Collectively, our data demonstrate SIRT2 and SIRT5 as novel 
interactors of MOAP-1 and suggest that in addition to ubiquitination and 
phosphorylation, MOAP-1 may be regulated by other PTMs such as 
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6.1 GENERAL DISCUSSION  
Protein abundance of MOAP-1 is regulated through the ubiquitin 
proteasome system (UPS) (67). Correspondingly, the up-regulation and 
ubiquitin-conjugated species of MOAP-1 can be readily observed in the 
presence of a proteasome inhibitor, MG132 (67). We showed the identification 
and characterization of tripartite motif protein 11 (TRIM11) as a putative E3 
ubiquitin ligase of MOAP-1. TRIM11 physically associates with and degrades 
MOAP-1 by poly-ubiquitinating MOAP-1 for degradation through the UPS. 
Targeted inactivation of TRIM11 E3 ubiquitin ligase activity by alanine 
substitution of conserved cysteine and histidine residues in the RING domain 
abolished its ability to poly-ubiquitinate and degrade MOAP-1. 
In the following chapter, we explored the prospective of 
phosphorylation as a regulatory mechanism for modulating the protein 
stability and function of MOAP-1. We showed that the protein stability of 
MOAP-1 is regulated by phosphorylation at serine-27 (Ser-27), Ser-29 and 
Ser-31. Constitutive phosphorylation at these sites by aspartate substitution 
prolongs the half-life of MOAP-1. In addition, we also identified the mitogen-
activated protein kinase kinase (MAPKK also referred to as MEK1) as 
MOAP-1-associating partner that stabilizes MOAP-1 through extension of 
MOAP-1 half-life. Notably, constitutive active form of MEK1, MEK1Δ-
mediated stabilization of MOAP-1 requires the constitutive phosphorylation at 
Ser-27, Ser-29 and Ser-31, supporting a role for MEK1 in modulating the 
protein stability of MOAP-1 through phosphorylation at these serine sites. 
Also, in agreement with its effect on enhancing MOAP-1 stability, over-
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expression of MEK1Δ sensitizes HCT116 cells to TRAIL-induced Bax-
activation and apoptosis. In this chapter, our data documented that 
phosphorylation is a regulatory mechanism in regulating the protein 
abundance and function of MOAP-1.   
In the first two chapters of results, we have separately explored and 
examined the potential role of ubiquitination and phosphorylation in 
regulating protein stability and function of MOAP-1. It has been widely 
acknowledged that PTMs regulate protein function in a highly orchestrated 
cascade of ubiquitination/de-ubiquitination events that are intermingled with 
other PTMs such as phosphorylation/de-phosphorylation or acetylation/de-
acetylation. Since phosphorylation of MOAP-1 has been shown to modulate 
its protein stability, it is highly conceivable that the phosphorylation status of 
MOAP-1 may regulate the interaction of MOAP-1 with its specific E3 
ubiquitin ligase, thereby controlling its protein abundance (Fig 6.1).     
Based on the experimental findings obtained in this study, we proposed 
that in healthy cells, TRIM11 associates with and degrades MOAP-1 by 
targeting MOAP-1 for degradation via the UPS. Since MOAP-1 has 
previously been demonstrated to be a critical effector for Bax-mediated 
apoptosis, elimination of MOAP-1 reduces the activation and oligomerization 
of Bax into the outer mitochondrial membrane thereby promoting cell survival. 
On contrary, DNA damaging agent, ETOP activates the MAPK signaling 
cascade leading to the sequential activation of MEK and ERK. 
Phosphorylation of MOAP-1 at Ser-27, Ser-29 and Ser31 stabilizes MOAP-1 
and is required for MEK1-mediated stabilization of MOAP-1. However, the 
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kinase(s) specifically responsible for phosphorylating these sites remain to be 
determined. Up to date, the only known physiological substrates of MEK1/2 
are ERK1/2 (258). Due to the substrate specificity of MEK1, it is unlikely that 
MEK1 itself functions as a MOAP-1 kinase. Instead, it is more likely that 
ERK1/2 may phosphorylate MOAP-1 directly or through activation of other 
downstream kinases. In contrary to our initial proposal that MOAP-1 may 
undergo a similar mode of regulation to Bim where phosphorylation is 
required for the subsequent ubiquitinated-mediated degradation, we proposed 
that phosphorylation of MOAP-1 at Ser-27, Ser-29 and Ser-31 inhibits the 
targeting of MOAP-1 by its E3 ubiquitin ligase for degradation through the 
UPS. The proposed disruption of interaction between MOAP-1 alanine mutant 
(S27,29,31A) and putative E3 ubiquitin ligase, TRIM11 remains to be 
validated in the future work. Correspondingly, under apoptotic condition, 
stabilized MOAP-1 associates with Bax and mediates its activation and 
oligomerization into the outer mitochondrial membrane which ultimately leads 
to mitochondrial outer membrane permeabilization, (MOMP), cytochrome c 
release and cell death.  




Figure 6.1 Proposed sequences of events during physiological condition (A) 
and ETOP-induced apoptosis (B). Figures are modified and adapted from 
(259). 
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In the last chapter of results, we identified SIRT2 and SIRT5, which 
are members of the sirtuin family of deacetylases, as novel interactors of 
MOAP-1. Our data also support a role for SIRT5 in mediating the regulation 
of MOAP-1 under DNA-damaging agent, ETOP. In addition, serum starvation 
abolished the interaction between MOAP-1 and SIRT5 suggesting a plausible 
role of MOAP-1 in modulating the activity of SIRT5 under normal 
physiological condition. The results obtained thus far are still insufficient to 
conclude whether acetylation may act as a regulatory mechanism to modulate 
the protein stability and function of MOAP-1.  
In summary, the work presented in this thesis has identified TRIM11, 
MEK1 and SIRT5 as potential regulators of MOAP-1. Interestingly, the 
known functions of these three proteins are distinctly different. While SIRT5 
has been reported to play a role in ammonia detoxification and exhibits 
deacetylase, demalonylase and desuccinylase activity, TRIM11 is believed to 
play a role in immunity and exhibits E3 ubiquitin ligase activity. In 
comparison, the role of MEK1 as a kinase has been demonstrated in regulating 
many fundamental cellular activities including cell survival, proliferation, 
differentiation and motility. The discrete distinction in the enzymatic activity 
of these potential regulators may open up windows of opportunities to 
strategize approaches to increase levels of MOAP-1 in cancer cells, thereby 
ensuring optimal Bax function in the mitochondrial-mediated apoptotic 
pathway.   
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6.2 FUTURE WORK 
6.2.1 Identification and characterization of TRIM11 as a putative E3 
ubiquitin ligase of MOAP-1 
Knockdown of endogenous TRIM11 in HEK293T cells did not alter 
the protein abundance of MOAP-1. However, this may be due to the low 
endogenous expression of TRIM11 in HEK293T cells. More cell-lines should 
be screened to investigate the effect of TRIM11 knock-down on the protein 
abundance of MOAP-1 under resting and apoptotic condition.    
 In addition, MOAP-1 has been reported to be a substrate of multi-unit 
E3 ubiquitin ligase, APC/C
Cdh1 
(104). In the paper, the authors showed that 
knock-down of Cdh1, activator of APC/C, using siRNA significantly slowed 
down the degradation of ectopic MOAP-1. It remains to be investigated if 
double knockdown of both TRIM11 and APC/C
Cdh1
 will synergize or have a 
redundancy effect on the protein abundance and function of MOAP-1. 
Similarly, since the scope of this study covers only the post-translational 
regulation of MOAP-1, additive experiments will be needed to assess the 
possibility whether TRIM11 can affect the transcription and translation of 
MOAP-1. In addition, future study may also investigate the interplay between 
TRIM39 and TRIM11 in regulating the protein stability of MOAP-1 via the 
UPS. In a recent review, it was proposed that TRIM family of proteins may 
possess scaffolding capabilities and be involved in self- and hetero-interaction, 
giving rise to a complex TRIM biochemical activity (261). In a similar context, 
it was reported that TRIM21 interacts with TRIM5 to ubiquitinate and degrade 
TRIM5 in HEK293 cells (262). Hence, future work may investigate if 
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TRIM11 and TRIM39 possess similar E3 ligase-substrate relationship. In 
addition, since TRIM39 and TRIM11 have been shown to exert opposing 
effects of MOAP-1, it would be interesting to evaluate the protein abundance 
of MOAP-1 under co-expression of both TRIM proteins.  
The field of de-ubiquitination is another area that may be looked into 
in the future work. At present, there is no evidence for a role of 
deubiquitinases in the molecular regulation of MOAP-1. Deubiquitinases 
catalyze the removal of ubiquitin moieties from proteins and hence may be 
used to nullify ubiquitylation signals, serving as an extra layer of control to 
regulate ubiquitination and to remove ubiquitin chains from substrate proteins 
prior to proteasomal degradation (263). It is possible that both ubiquitination 
and de-ubiquitination occur at a very rapid exchange process thereby 
providing an extremely dynamic ubiquitination response (263). 
 6.2.2 Evaluation of phosphorylation as a regulatory mechanism to 
modulate protein stability of MOAP-1 
While the work presented in this thesis has investigated specifically on 
the potential role of phosphorylation in regulating the protein stability of 
MOAP-1, phosphorylation may also modulate many other aspects of a protein 
including its intrinsic functional activity, folding and conformation, 
oligomerization state, sub-cellular localization and its interaction with other 
cellular molecules in the cell. Future analysis may look into the impact of 
phosphorylation on the sub-cellular localization and apoptotic function of 
MOAP-1.  
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In the in vitro phosphorylation experiment, though a band 
corresponding to the molecular weight of GST-MOAP-1 was detected (Fig 
4.2), mass spectrometry analysis of the brain lysates was not conducted to 
identify potential kinase(s) which may have phosphorylated MOAP-1 in the 
kinase reaction. This may be investigated in the future to identify downstream 
kinases of MEK which may function as direct kinase(s) of MOAP-1.  
Constitutive active MEK1 associates with and stabilizes MOAP-1. In 
addition, phosphorylation of MOAP-1 at Ser-27, Ser-29 and Ser31 is required 
for MEK1-mediated stabilization of MOAP-1. However due to the substrate 
specificity of MEK1, it is unlikely that MEK1 itself functions as a MOAP-1 
kinase. Therefore, future work can be carried out to identify and validate if 
ERK1/2 or its downstream kinase are putative kinase of MOAP-1. In addition, 
knock-down gene analysis of MEK could be conducted to further support and 
validate the role of MEK in regulating the protein stability of MOAP-1. In 
addition, constitutive phosphorylation of MOAP-1 at Ser-27, Ser-29 and Ser31 
by aspartate substitution stabilizes MOAP-1. Since our data showed that 
TRIM11 interacts with and degrades MOAP-1 through the UPS it is proposed 
that future work can be carried out to investigate if phosphorylation at the 
three serine sites abolishes the interaction between MOAP-1 and TRIM11, 
thereby preventing the poly-ubiquitination and consequent degradation of 
MOAP-1.  
Similar to de-ubiquitination, the field of de-phosphorylation is an area 
that can be further examined. Up to date, there is no evidence to support a role 
of phosphatase in the molecular regulation of MOAP-1. Similar to many other 
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Bcl-2 family proteins which have been reported to be regulated by reversible 
phosphorylation, it is conceivable that both phosphorylation and de-
phosphorylation work cooperatively on MOAP-1 to regulate its protein 
abundance and function as a pro-apoptotic protein in different cellular contexts.  
Correspondingly, since the scope of this study covers only the post-
translational regulation of MOAP-1, additive experiments will be needed to 
assess the possibility whether MEK1 can affect the transcription and 
translation of MOAP-1. 
6.2.3 Identification of Sirtuins as novel interactors and regulators of 
MOAP-1  
SIRT2 and SIRT5 are members of the sirtuin family of deacetylases. 
Novel interactions between endogenous MOAP-1 and SIRT2 and SIRT5 were 
observed. Given that SIRT2 and SIRT5 have been reported to deacetylate 
many key metabolic proteins, it remains to be investigated whether MOAP-1 
may be a substrate of deacetylation by either or both SIRT2 and SIRT5. 
Notably, SIRT2 has been linked to the regulation of many cellular processes 
such as adipocyte differentiation through the modulation of FOXO1 
acetylation and activity (264). It would be interesting to investigate if MOAP-
1 may synergize with SIRT2, promoting its regulation on FOXO1 thereby 
playing a role in controlling adipose tissue mass and function.  
In addition, it is an interesting observation that serum starvation 
abolished the interaction between endogenous MOAP-1 and SIRT5. Notably, 
SIRT5 has been reported to deacetylate and activate carbamoyl phosphate 
synthetase 1 (CPS1) after 48 hours of fasting (172). CPS1 catalyzes the initial 
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step of the urea cycle for ammonia detoxification and disposal and hence is a 
committed and regulated enzyme of the urea cycle (265,266). It would be 
interesting to investigate if MOAP-1 associates with SIRT5 to sequester 
SIRT5 under high nutrients condition. Whereas during fasting condition, the 
interaction between MOAP-1 and SIRT5 is promptly disrupted, releasing 
SIRT5 to deacetylate and activate CPS1. Interestingly, SIRT5 selectively 
blocked ETOP-mediated up-regulation of MOAP-1. Since SIRT5 possess 
deacetylation activity, it is conceivable that acetylation of MOAP-1 may be 
required for its ETOP-mediated up-regulation. Notably, it was reported that in 
addition to its function as a deacetylase, SIRT5 may also act as demalonylase 
and desuccinylase (153), giving rise possibility that MOAP-1 may be 
regulated by malonylation and succinylation too. These are areas that could be 














The findings of this Ph.D. study have provided further insights to 
enhance our understanding of the mechanisms that serve to regulate MOAP-1 
stability (Fig 6.1). While TRIM11 may function as an E3 ubiquitin ligase to 
target MOAP-1 to the UPS, the activation of MEK1 potentially results in the 
phosphorylation of MOAP-1 which prevents its degradation via the UPS. 
Lastly, more work will be required to verify if direct deacetylation of MOAP-
1 by SIRT5 can be observed. The identification of these novel molecules 
including TRIM11, MEK1 and SIRT5 may serve as valuable leads to reveal 
the detailed mechanisms by which apoptotic signals regulate protein stability 
of MOAP-1. As such, this would aid in strategizing approaches to elevate 
levels of MOAP-1 in cancer cells, thereby ensuring optimal Bax functioning 
and consequently increasing the sensitivity of cancer cells to chemo-
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